WO2024072316A1 - Co-culture of human induced pluripotent stem cell (hipsc) − derived macrophages and hepatocytes for generation of hipsc-kupffer cells - Google Patents
Co-culture of human induced pluripotent stem cell (hipsc) − derived macrophages and hepatocytes for generation of hipsc-kupffer cells Download PDFInfo
- Publication number
- WO2024072316A1 WO2024072316A1 PCT/SG2022/050696 SG2022050696W WO2024072316A1 WO 2024072316 A1 WO2024072316 A1 WO 2024072316A1 SG 2022050696 W SG2022050696 W SG 2022050696W WO 2024072316 A1 WO2024072316 A1 WO 2024072316A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liver
- ipsc
- derived
- ikc
- cell
- Prior art date
Links
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title claims abstract description 116
- 210000004027 cell Anatomy 0.000 title claims abstract description 99
- 210000003494 hepatocyte Anatomy 0.000 title claims abstract description 59
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 52
- 241000282414 Homo sapiens Species 0.000 title claims description 22
- 238000003501 co-culture Methods 0.000 title description 26
- 210000001865 kupffer cell Anatomy 0.000 claims abstract description 117
- 238000000034 method Methods 0.000 claims abstract description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 230000004044 response Effects 0.000 claims abstract description 13
- 230000001404 mediated effect Effects 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 210000004185 liver Anatomy 0.000 claims description 49
- 239000003550 marker Substances 0.000 claims description 49
- 230000014509 gene expression Effects 0.000 claims description 39
- 239000001963 growth medium Substances 0.000 claims description 37
- 101100127285 Drosophila melanogaster unc-104 gene Proteins 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 27
- 230000018109 developmental process Effects 0.000 claims description 25
- 102000004311 liver X receptors Human genes 0.000 claims description 25
- 108090000865 liver X receptors Proteins 0.000 claims description 25
- 238000011161 development Methods 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 23
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 23
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 22
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 22
- 208000019423 liver disease Diseases 0.000 claims description 22
- 230000008929 regeneration Effects 0.000 claims description 19
- 238000011069 regeneration method Methods 0.000 claims description 19
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 18
- 102000004889 Interleukin-6 Human genes 0.000 claims description 17
- 108090001005 Interleukin-6 Proteins 0.000 claims description 17
- 231100000753 hepatic injury Toxicity 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 17
- 206010067125 Liver injury Diseases 0.000 claims description 16
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 16
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 15
- 108090000695 Cytokines Proteins 0.000 claims description 15
- 230000019491 signal transduction Effects 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 229930182555 Penicillin Natural products 0.000 claims description 13
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 13
- 229940049954 penicillin Drugs 0.000 claims description 13
- 102000004140 Oncostatin M Human genes 0.000 claims description 12
- 108090000630 Oncostatin M Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000003636 conditioned culture medium Substances 0.000 claims description 12
- 206010008635 Cholestasis Diseases 0.000 claims description 11
- 208000004930 Fatty Liver Diseases 0.000 claims description 11
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims description 11
- 206010019799 Hepatitis viral Diseases 0.000 claims description 11
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 claims description 11
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 claims description 11
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 11
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 11
- 206010027476 Metastases Diseases 0.000 claims description 11
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 claims description 11
- 108010066463 Retinoid X Receptor alpha Proteins 0.000 claims description 11
- 231100000359 cholestasis Toxicity 0.000 claims description 11
- 230000007870 cholestasis Effects 0.000 claims description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 201000007270 liver cancer Diseases 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 201000001862 viral hepatitis Diseases 0.000 claims description 11
- 102100038495 Bile acid receptor Human genes 0.000 claims description 10
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 10
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 9
- 239000007995 HEPES buffer Substances 0.000 claims description 9
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 9
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 9
- 229960000681 leflunomide Drugs 0.000 claims description 9
- 229960005322 streptomycin Drugs 0.000 claims description 9
- 229960000894 sulindac Drugs 0.000 claims description 9
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 9
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims description 8
- 229960001444 amodiaquine Drugs 0.000 claims description 8
- 229960001259 diclofenac Drugs 0.000 claims description 8
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 8
- 229960001848 lamotrigine Drugs 0.000 claims description 8
- 108010009992 CD163 antigen Proteins 0.000 claims description 7
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 7
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 7
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims description 6
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims description 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 6
- 102000000513 Inhibitor of Differentiation Protein 1 Human genes 0.000 claims description 6
- 108010055965 Inhibitor of Differentiation Protein 1 Proteins 0.000 claims description 6
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 6
- 102100025136 Macrosialin Human genes 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 102100039436 DNA-binding protein inhibitor ID-3 Human genes 0.000 claims description 5
- 101710152064 DNA-binding protein inhibitor ID-3 Proteins 0.000 claims description 5
- 231100000334 hepatotoxic Toxicity 0.000 claims description 5
- 230000003082 hepatotoxic effect Effects 0.000 claims description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 3
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 102000013691 Interleukin-17 Human genes 0.000 claims description 2
- 102000003810 Interleukin-18 Human genes 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 claims description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 2
- 229960003459 allopurinol Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000590 celecoxib Drugs 0.000 claims description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 2
- 229940090805 clavulanate Drugs 0.000 claims description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 2
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 claims description 2
- 229960001489 deferasirox Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002877 dihydralazine Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 229960004273 floxacillin Drugs 0.000 claims description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003132 halothane Drugs 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 229960000689 nevirapine Drugs 0.000 claims description 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 2
- 229960000564 nitrofurantoin Drugs 0.000 claims description 2
- 229960002036 phenytoin Drugs 0.000 claims description 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 2
- 229960001589 posaconazole Drugs 0.000 claims description 2
- 229960002662 propylthiouracil Drugs 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 2
- 229960001225 rifampicin Drugs 0.000 claims description 2
- 229960005224 roxithromycin Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000008859 change Effects 0.000 description 18
- 229940100601 interleukin-6 Drugs 0.000 description 16
- 230000037361 pathway Effects 0.000 description 13
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
- 230000002440 hepatic effect Effects 0.000 description 12
- 239000013589 supplement Substances 0.000 description 12
- 102100027211 Albumin Human genes 0.000 description 11
- 108010088751 Albumins Proteins 0.000 description 11
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 8
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 6
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001146 hypoxic effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000003068 pathway analysis Methods 0.000 description 6
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 5
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 5
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 5
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 5
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 5
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 5
- 238000010874 in vitro model Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229960005206 pyrazinamide Drugs 0.000 description 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 101150027068 DEGS1 gene Proteins 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100030612 Mast cell carboxypeptidase A Human genes 0.000 description 3
- 101710119290 Mast cell carboxypeptidase A Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 210000003547 hepatic macrophage Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000001617 migratory effect Effects 0.000 description 3
- 238000009343 monoculture Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 210000004738 parenchymal cell Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 102100032309 A disintegrin and metalloproteinase with thrombospondin motifs 15 Human genes 0.000 description 2
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 102100035337 Bone marrow proteoglycan Human genes 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 2
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 description 2
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 2
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 2
- 102100028556 Disheveled-associated activator of morphogenesis 2 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 101000798294 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 15 Proteins 0.000 description 2
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000915408 Homo sapiens Disheveled-associated activator of morphogenesis 2 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 108010087367 P-glycoprotein 2 Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102100027980 Semaphorin-3C Human genes 0.000 description 2
- 101710199433 Semaphorin-3C Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000001968 dental pulp cell Anatomy 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000012245 hepatotoxicant Substances 0.000 description 2
- 231100001114 hepatotoxicant Toxicity 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 102000004114 interleukin 20 Human genes 0.000 description 2
- 108090000681 interleukin 20 Proteins 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 241000945470 Arcturus Species 0.000 description 1
- 101150075175 Asgr1 gene Proteins 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 101710134771 Bone marrow proteoglycan Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100021056 Ferroptosis suppressor protein 1 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101001095043 Homo sapiens Bone marrow proteoglycan Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000818014 Homo sapiens Ferroptosis suppressor protein 1 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001131990 Homo sapiens Peroxidasin homolog Proteins 0.000 description 1
- 101000582986 Homo sapiens Phospholipid phosphatase-related protein type 3 Proteins 0.000 description 1
- 101001123334 Homo sapiens Proteoglycan 3 Proteins 0.000 description 1
- 101000620880 Homo sapiens Tartrate-resistant acid phosphatase type 5 Proteins 0.000 description 1
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 101001123335 Mus musculus Proteoglycan 3 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000014105 Semaphorin Human genes 0.000 description 1
- 108050003978 Semaphorin Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the invention relates to a method of generating Kupffer cells from pluripotent stem cells. Specifically, the invention relates to a method of co-culturing pluripotent stem cell derived macrophages and pluripotent stem cell derived hepatocytes to generate Kupffer cells. BACKGROUND OF THE INVENTION [0002] Liver-resident Kupffer cells (KCs) form a major population of hepatic macrophages.
- liver injury and repxyxy KCs are involved in maintaining liver homeostasis and contributing to progression of hepatic injury in the absence and presence of external stimuli respectively.
- stimuli from foreign particles/bacterial endotoxins are endocytosed by KCs; consecutively, cell damage or soluble stress signals leads to KC activation and production of cell signaling and stress pathway modulators, including reactive oxygen species and cytokines.
- KC activation also regulates parenchymal hepatic and non-parenchymal cell death by apoptosis and metabolic activity of hepatocytes.
- liver parenchymal cells hepatocytes
- KCs non- parenchymal modulators
- iPSC Induced pluripotent stem cell
- iKCs Induced pluripotent stem cell
- PHCM primary hepatocytes
- iMacs iPSC-derived macrophages
- PHCM primary hepatocytes
- iKCs functionally resembled PhKCs
- PHCM is expensive due to the cost of primary cell culture and exhibit differences depending on donor variability of primary hepatocytes.
- a method of generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising the steps of: (a) providing an iPSC- derived macrophage (iMac); (b) providing an iPSC-derived hepatocyte (iHep); (c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate the iKC.
- iPSC induced pluripotent stem cell
- iKC induced pluripotent stem cell
- kits when used in the method as described herein for generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising: (a) an iPSC-derived macrophage (iMac); (b) an iPSC-derived hepatocyte (iHep); and (c) a premixed cell culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAX TM and about 30mM HEPES buffer with instructions for use.
- iPSC induced pluripotent stem cell
- iKC induced pluripotent stem cell
- iMac iPSC-derived macrophage
- iHep iPSC-derived hepatocyte
- a premixed cell culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAX TM and about 30mM HEPES buffer with instructions for use.
- iPSC induced pluripotent stem cell
- iKC induced pluripotent stem cell
- iHep iPSC-derived hepatocyte
- a method of detecting an immune-mediated response to an agent comprising the steps of: (a) providing an iPSC-derived macrophage (iMac); (b) providing an iPSC-derived hepatocyte (iHep); (c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate a combined cell population comprising an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC); (d) contacting and incubating the combined cell population from step (c) with the agent; (e) detecting the presence or absence of a marker or measuring a level of said marker to detect the immune-mediated response to the agent.
- iPSC iPSC-derived macrophage
- iHep iPSC-derived hepatocyte
- iKC induced pluripotent stem cell
- iKC induced pluripotent stem cell
- a method of treating a liver disease in a subject in need thereof wherein an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein is to be administered to said subject, wherein the disease is selected from the group consisting of: liver injury, drug- induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver.
- DILI drug- induced liver injury
- liver disease steatohepatitis
- cholestasis cholestasis
- liver fibrosis viral hepatitis
- liver cancer primary hepatocellular carcinoma
- iPSC induced pluripotent stem cell
- iKC iPSC-derived Kupffer cell
- iHep iPSC-derived hepatocyte
- a liver disease selected from the group consisting of: liver injury, drug- induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal met
- iPSC induced pluripotent stem cell
- iKC iPSC-derived Kupffer cell
- iHep iPSC-derived hepatocyte
- the process of generating iPSCs typically involves introducing products of specific sets of pluripotency-associated genes, or "reprogramming factors".
- the somatic cells used to derive the stem cells may include but are not limited to liver macrophages, Kupffer cells, fibroblasts, myoblasts, keratinocytes, melanocytes, hepatocytes, ⁇ -cells, dental pulp cells, blood cells and urine-derived renal epithelial cells.
- the stem cells as used herein may include but are not limited to human, non- human primate, murine and avian stem cells.
- the term “differentiate” refers to the developmental process by which a cell has progressed further down a developmental pathway than its immediate precursor cell.
- a differentiated cell is a cell of a more specialized cell type derived from a cell of a less specialized cell type in a cellular differentiation process.
- a differentiated cell is one that has taken on a more committed position within the lineage of the cell.
- macrophage refers to a mononuclear phagocyte that recognizes, ingests and degrades cellular debris, microbes or any other foreign materials in a process termed phagocytosis. Macrophages are the most abundant liver immune cells and play a key role in tissue homeostasis and immunity.
- Embryonically-derived Kupffer cells (KCs) are the main population of macrophages of the liver and express liver specific markers.
- Monocyte-derived macrophages exist in the liver but represent a minor population of macrophages that increase during inflammation.
- hepatocyte refers to a primary liver cell or hepatic parenchymal cell that is involved in metabolic processes. Hepatocytes comprise up to 80% of the total cell population of the human liver. Some of the metabolic processes that hepatocytes are involved in include carbohydrate metabolism, for example glycogen synthesis, glycolysis, and drug metabolism.
- the term “Kupffer cells” refers to the self-renewing, resident and principally non-migratory phagocyte population in the liver.
- Kupffer cells originate from yolk sac-derived specific progenitor cells that seed the liver during embryogenesis. Kupffer cells are innate immune cells in the liver. Some of the important roles that Kupffer cells are involved in include scavenging for foreign materials and phagocytosis of cellular debris, foreign material or pathogens and maintenance of iron homeostasis via phagocytosis of red blood cells and recycling of iron. As such, they are regarded as critical sentinels that ensure liver homeostasis and eliminate antibodies, debris or dead cells. In healthy livers, Kupffer cells are exclusively located in the intravascular compartment (mainly within the hepatic sinusoids).
- iMac refers to induced pluripotent stem cell (iPSC)- derived macrophage.
- iPSC induced pluripotent stem cell
- iMacs are derived by differentiation of iPSCs according to the method described in Takata et al., (2017). Specifically, the iPSCs were cultured to 80% confluency, then passaged using ReLESR. As ReLESR releases the cells as small cell clumps, the passage conditions were optimised to result in roughly 1 x 10 5 cells in each well of a 6 well plate (Day -1).
- Stempro Media consisting of Stempro-34 SFM (GIBCO, 10639-011), supplemented with 200 ug/mL Human Transferrin (Roche, 10-652-202-001), 1x L-Glut, 1x Pen/Strep, 0.5 mM Ascorbic Acid (Sigma, A4544) and 0.45mM MTG (Sigma, M6145).
- Differentiation Day 0 (5 ng/mL BMP4, 50 ng/mL VEGF, and 2 ⁇ M CHIR99021
- Differentiation Day 2 (5 ng/mL BMP4, 50 ng/mL VEGF, and 20 ng/mL FGF2)
- Differentiation Day 4 (15 ng/mL VEGF and 5 ng/mL FGF2)
- Differentiation Day 6 to 10 (10 ng/mL VEGF, 10 ng/mL FGF2, 50 ng/mL SCF, 30 ng/mL DKK-1 (RnD, 5439-DK), 10 ng/mL IL-6 (RnD, 206-IL), and 20 ng/mL IL-3
- Differentiation Day 12 and 14 (10 ng/mL FGF2, 50 ng/mL SCF, 10 ng/mL IL-6, and 20 ng/mL IL-3).
- the cells were cultured in 75% IMDM with GlutaMAX TM (GIBCO, 31980-030), 25% F12 (GIBCO, 11765- 047), 1x N2 supplement (GIBCO, 17502-048), 1x B27 Supplement (GIBCO, 17504-001), 0.05% BSA (GE Healthcare, SH30574) and 1x Pen/Strep, supplemented with 50ng/ml of CSF-1 (RnD, 216-MC), with a full media change every 3 days.
- the cells were kept in a hypoxic incubator (5% O 2 and 5% C O 2 ), before being transferred to a standard cell culture incubator for the next 18 days.
- iHep refers to an induced pluripotent stem cell (iPSC)- derived hepatocyte. According to the method as described in Cai et al., (2015), iHeps are derived by differentiation of iPSCs.
- the iPSCs were cultured to 80% confluency, then made into single cells using Cell Dissociation Buffer (Gibco, 13151014) and seeded at 1.5 x 10 5 cells/cm 2 on the desired well plate format (i.e.1.5 x 10 6 cells for a 6 well plate) and placed under hypoxic conditions (5% O 2 and 5% CO 2 ). The cells are seeded onto appropriate plate and cultured overnight under the hypoxic conditions as described herein. The day after the culture overnight is referred to as differentiation day 1.
- Cell Dissociation Buffer Gibco, 13151014
- hypoxic conditions 5% O 2 and 5% CO 2
- culture medium was removed and replaced with RPMI/B-27 (minus Insulin) (Invitrogen/Gibco) supplemented with 100 ng/ml Activin A (R&D systems), 10 ng/mL BMP4 (Peprotech) and 20 ng/mL FGF2 (Invitrogen).
- Culture medium was changed daily and cultured for 2 days at 37°C in ambient O 2 /5% CO 2.
- culture medium was changed to RPMI/B-27 (minus Insulin) supplemented with 100 ng/ml Activin A and continued to culture for an additional 3 days at 37°C in ambient O 2 /5% CO 2 with daily medium changes.
- culture medium was changed to RPMI/B27 (complete with Insulin) supplemented with 20 ng/ml BMP-4 and 10 ng/ml FGF2. Culture was incubated for 5 days at 37°C in 4% O 2 /5% CO 2 and culture medium was replaced daily for a total of 5 days.
- culture medium was changed to RPMI/B27 (complete with Insulin) supplemented with 20 ng/ml Hepatocyte Growth Factor (HGF) (Peprotech). Culture was incubated for 5 days at 37°C in 4% O 2 /5% CO 2 and medium was replaced daily.
- HGF Hepatocyte Growth Factor
- HCM Hepatocyte Culture Medium
- kit supplements 20 ng/ml Oncostatin-M (R&D Systems) was added. Culture was incubated for 5 days at 37°C in ambient O 2 /5% CO 2 and culture medium was replaced daily. After 20 days of differentiation, iPSC-derived macrophages (iMacs) were directly added to the iHeps.
- iPSC-derived macrophages iMacs
- the term “subject” or “patient” refers to all animals classified as mammals and includes but is not limited to primates, humans, cows, horses, pigs, sheep, goats, dogs, cats, or rodents. Preferably, the subject is a human man or woman of any age or race.
- the term “treatment”, refers to any type of therapy, which aims at terminating, preventing, ameliorating or reducing the susceptibility to a clinical condition as described herein. The effect may be prophylactic in terms of completely or partially preventing a disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse effect attributable to the disorder.
- treatment includes preventing the disorder from occurring or recurring in a subject, inhibiting the disorder, such as arresting its development, stopping or terminating the disorder or at least symptoms associated therewith, so that the host no longer suffers from the disorder or its symptoms, such as causing regression of the disorder or its symptoms, for example, by restoring or repairing a lost, missing or defective function, or stimulating an inefficient process, or relieving, alleviating, or ameliorating the disorder, or symptoms associated with the disorder.
- the term “about”, is used in the context of, but not limited to, concentrations of components and percentages of compounds. Throughout this disclosure, certain embodiments may be disclosed in a range format.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub- ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- Figure 1 depicts the model development and shows a schematic of the experimental layout.
- Figure 2 shows the assessment of hepatocyte performance as a function of media supplementation.
- Figure 2A shows gene expression of hepatic markers upon treatment with media supplemented 2X and media changed performed every day, every other day or every two days.
- Figure 2B shows hepatic marker expression with 2X media supplementation and 2X media volume to account for the infrequent media change. Gene expression was compared as fold change to standard hepatocyte culture conditions (daily media change with 1X supplement and standard media volume).
- Figure 2C shows albumin and urea production when hepatocytes were harvested and reseeded for experimental set up compared to unharvested hepatocytes (in situ), demonstrating that hepatocytes harvesting does not compromise cell functionality.
- Figure 3 shows the effects of iHeps on iMacs.
- Figure 3A shows the Principal Component Analysis of bulk RNAseq data from Day 0 iMacs, Day 3 co-iMacs, Day 7 co- iMacs, Day 7 iMacs and Day 7 cond-iMacs.
- Figure 3B shows the heatmap showing the top 5 differentially and uniquely expressed genes from culturing iMacs alone, with conditioned media (cond-iMacs) and after co-culture with iHepatocytes (Day 7 co-iMacs).
- Figure 3C shows the volcano plot showing differentially-expressed genes between Day 0 iMacs and Day 7 co-iMacs.
- Figure 3D shows the differentially expressed upregulated pathways between Day 0 iMacs and Day 7 co-iMacs.
- Figure 3E shows the volcano plot showing differentially-expressed genes between Day 7 cond-iMacs and Day 7 co-iMacs.
- Figure 3F shows the differentially expressed upregulated pathways between Day 7 cond-iMacs and Day 7 co-iMacs.
- Figure 3G shows the Gene expression levels of LYVE1, ID1, ID3, RXRA, HBEGF and OSM in Day 0 iMacs, Day 3 co-iMacs, Day 7 co-iMacs, Day 7 iMacs and Day 7 cond-iMacs.
- Figure 4 shows the gene expression of iMac and iHep markers in co-cultures.
- Figure 4A shows the expression of macrophage markers (top panel) and KC-specific markers (bottom panel) on day 3 and day 7 of co-culture.
- Figure 4B shows the expression of macrophage markers (top panel) and KC-specific markers (bottom panel) on day 7 of co- culture compared to iMac cultured in PHCM.
- Figure 4C shows the expression of hepatic markers on day 3 and day 7 of co-culture. * p ⁇ 0.05.
- Figure 6 shows the changes in IL-6 level upon treatment with 7 paradigm compounds without iMac-derived KCs.
- the present invention refers to a method of generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising the steps of (a) providing an iPSC-derived macrophage (iMac); (b) providing an iPSC-derived hepatocyte (iHep); (c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate the iKC.
- the iKC may demonstrate one or more biological characteristics or phenotypes of a Kupffer cell (KC).
- the biological characteristic of a KC may be an expression of a macrophage marker, an expression of a KC marker, an expression of a Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signaling pathway regulator, an expression of a marker for liver regeneration and/or development, or combinations thereof.
- LXR/RXR Liver X Receptor/Farnesoid X Receptor
- the iKC may express one or more macrophage markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more KC markers and one or more LXR/RXR signal pathway regulators. In another example, the IKC may express one or more KC markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more LXR/RXR signal pathway regulators and one or more markers for liver regeneration and/or development. [0034] In some examples, the macrophage marker may be but is not limited to CD68, CD163, CD11b, CD32 and CD14. It will be appreciated by a person skilled in the art that iKC may express one or more macrophage markers.
- iKC may express combinations of macrophage markers.
- the KC marker may be but is not limited to Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA-binding protein inhibitor ID-1 (ID1), and DNA-binding protein inhibitor ID-3 (ID3).
- LYVE1 Lymphatic Vessel Endothelial Hyaluronan Receptor 1
- ID1 DNA-binding protein inhibitor ID-1
- ID3 DNA-binding protein inhibitor ID-3
- iKC may express one or more KC markers.
- iKC may express combinations of KC markers.
- the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator may be but is not limited to Retinoid X Receptor Alpha (RXRA).
- the marker for liver regeneration and/or development may be but is not limited to Heparin Binding EGF Like Growth Factor (HBEGF) and Oncostatin M (OSM).
- HEGF Heparin Binding EGF Like Growth Factor
- OSM Oncostatin M
- iKC may express one or more markers for liver regeneration and/or development.
- iKC may express combinations of markers for liver regeneration and/or development.
- the number of iHeps to iMacs may be cultured at a ratio of about 1:1: to about 10:1.
- the ratio of iHeps to iMacs may be about 1:1, about 1.5:1, about 2:1, about 2.5:1, about 3:1, about 3.5:1, about 4:1, about 4.5:1, about 5:1, about 5.5:1, about 6:1, about 6.5:1, about 7:1, about 7.5:1, about 8:1, about 8.5:1, about 9:1, about 9.5:1, about 10:1.
- the ratio of iHeps to iMacs is about 2.5:1.
- the iHeps and iMacs may be incubated on a cell culture plate.
- the culture plate may be a 6-well plate, 12-well plate, 24-well plate, 48-well plate or 96-well plate.
- the iHeps and iMacs may be incubated on a culture dish.
- the culture dish may be a 35mm dish, 60mm dish, 100mm dish or 150mm culture dish.
- the iHeps and iMacs may be incubated in a culture flask.
- the culture flask may be a T25 flask, T75 flask, T175 flask or T225 flask.
- ECM extracellular matrix
- the iHeps and iMacs may be cultured on a 6-well plate.
- the iHeps and iMacs may be cultured on a Matrigel-coated 6-well plate or an extracellular matrix (ECM)-coated 6-well plate.
- ECM extracellular matrix
- the number of iHeps and iMacs cultured on a 6-well plate is about 5 x 10 5 and about 2 x 10 5 respectively. It will be appreciated by a person skilled in the art that the cell density of iHeps and iMacs to be cultured can be scaled proportionately based on the surface area of the culture vessel used.
- the total number of iHeps and iMacs cultured on a 6-well plate is up to 1.5 x 10 6 . It will be appreciated by a person skilled in the art that the cell density of iHeps and iMacs to be cultured can be scaled proportionately based on the surface area of the culture vessel used. [0044] In some examples, the concentration of the Penicillin/Streptomycin in the culture medium may be between 0.1% and about 3%.
- the concentration of the Penicillin/Streptomycin may be about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, and about 3.0%.
- the concentration of Penicillin/Streptomycin is about 1.0%.
- the concentration of the ITS in the culture medium may be between 0.1% and about 4%.
- the concentration of the ITS may be about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, about 3.0%, about 3.1%, about 3.2%, about 3.3%, about 3.4%, about 3.5%, about 3.6%, about 3.7%, about 3.8%, about 3.9% and about 4.0%.
- the concentration of ITS is about 2.0%.
- the concentration of the GlutaMAX TM in the culture medium may be between 1mM and about 7mM.
- the concentration of the GlutaMAX TM may be about 1.0mM, about 1.1mM, about 1.2mM, about 1.3mM, about 1.4mM, about 1.5mM, about 1.6mM, about 1.7mM, about 1.8mM, about 1.9mM, about 2.0mM, about 2.1mM, about 2.2mM, about 2.3mM, about 2.4mM, about 2.5mM, about 2.6mM, about 2.7mM, about 2.8mM, about 2.9mM, about 3.0mM, about 3.1mM, about 3.2mM, about 3.3mM, about 3.4mM, about 3.5mM, about 3.6mM, about 3.7mM, about 3.8mM, about 3.9mM, about 4.0mM, about 4.1mM, about 4.2mM, about 4.3mM, about 4.4mM
- the concentration of GlutaMAX TM is about 4.0mM.
- the concentration of the HEPES buffer in the culture medium may be between 5mM and 50mM.
- the concentration of the HEPES buffer may be about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM, about 20mM, about 21mM, about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM
- the concentration of HEPES buffer is about 30mM.
- the iHep and iMac are incubated with culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAX TM and about 30mM HEPES buffer.
- the culture medium may contain CSF-1.
- the culture medium does not contain dexamethasone.
- the concentration of the CSF-1 in the culture medium may be between 25ng/mL to 75ng/mL.
- the concentration of the CSF-1 may be about 25ng/mL, about 26ng/mL, about 27ng/mL, about 28ng/mL, about 29ng/mL, about 30ng/mL, about 31ng/mL, about 32ng/mL, about 33ng/mL, about 34ng/mL, about 35ng/mL, about 36ng/mL, about 37ng/mL, about 38ng/mL, about 39ng/mL, about 40ng/mL, about 41ng/mL, about 42ng/mL, about 43ng/mL, about 44ng/mL, about 45/mL, about 46ng/mL, about 47ng/mL, about 48ng/mL, about 49ng/mL, about 50ng/mL, about 51ng/mL, about 52ng/mL, about 53ng/mL, about 54ng/mL, about 55ng/mL, about 56ng/mL, about 57ng/mL, about 58ng/mL, about 59ng
- the concentration of CSF-1 is about 50ng/mL.
- the culture medium does not contain primary hepatocyte conditioned media.
- the primary hepatocyte conditioned media refers to culture media used in culturing primary hepatocytes.
- the iPSCs may be human iPSCs. In one example, the iPSCs may be but is not limited to IMR90-F4, IMR90-iPSCs, Kyou-DXR0109B, PCi-ASI and PCi- CAU.
- the iPSC may be derived or reprogrammed from a somatic cell obtained from a subject or patient.
- the volume of culture media per well of a 6-well plate may be between 2.0mL to 6.0mL.
- the volume of culture media per well of a 6-well plate may be about 2.0mL, about 2.1mL, about 2.2mL, about 2.3mL, about 2.4mL, about 2.5mL, about 2.6mL, about 2.7mL, about 2.8mL, about 2.9mL, about 3.0mL, about 3.1mL, about 3.2mL, about 3.3mL, about 3.4mL, about 3.5mL, about 3.6mL, about 3.7mL, about 3.8mL, about 3.9mL, about 4.0mL, about 4.1mL, about 4.2mL, about 4.3mL, about 4.4mL, about 4.5mL, about 4.6mL, about 4.7mL, about 4.8mL, about 4.9mL, about 5.0mL, about 5.1mL, about 5.2mL, about 5.3mL, about 5.4mL, about 5.5mL, about 5.6mL, about 5.7mL, about 5.8mL, about 5.9mL, about
- the volume of culture media per well of a 6-well plate is 4.0mL.
- the iHep and iMac may be cultured for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 days, wherein day 0 refers to the day iHep and iMac are in contact and cultured in a single culture vessel.
- the iHep and iMac are cultured for 7 days.
- about 2mL of culture media is aspirated from a well in the 6- well culture plate and replaced with about 2mL of newly prepared culture media of the same on or after day 4.
- volume of culture media aspirated can be scaled proportionately based on the volumetric size of the culture vessel used.
- a person skilled in the art will understand to replace the aspirated culture media with an equal volume of freshly prepared culture media of the same. In one example, 2mL of culture media is aspirated from the 6-well culture plate and replaced with 2mL of newly prepared culture media of the same on day 4.
- kits when used in the method as described herein, for generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC), comprising: (a) an iPSC-derived macrophage (iMac); (b) an iPSC-derived hepatocyte (iHep); and (c) a premixed cell culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAX TM and about 30mM HEPES buffer with instructions for use.
- iPSC induced pluripotent stem cell
- iKC induced pluripotent stem cell
- iMac iPSC-derived macrophage
- iHep iPSC-derived hepatocyte
- a premixed cell culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAX TM and about 30mM HEPES buffer with instructions for use.
- an induced pluripotent stem cell (iPSC)- derived Kupffer cell (iKC) obtained by the method as described herein.
- the iKC may express higher levels of KC-specific markers compared to an iMac cultured in primary hepatocyte conditioned media.
- the iKC may express one or more biological characteristics of a Kupffer cell (KC).
- the biological characteristic of a KC may be an expression of a macrophage marker, an expression of a KC marker, an expression of a Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signaling pathway regulator, an expression of a marker for liver regeneration and/or development, or combinations thereof.
- LXR/RXR Liver X Receptor/Farnesoid X Receptor
- the iKC may express one or more macrophage markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more KC markers and one or more LXR/RXR signal pathway regulators. In another example, the IKC may express one or more KC markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more LXR/RXR signal pathway regulators and one or more markers for liver regeneration and/or development [0062] In some examples, the macrophage marker may be but is not limited to CD68, CD163, CD11b, CD32 and CD14. It will be appreciated by a person skilled in the art that iKC may express one or more macrophage markers.
- iKC may express combinations of macrophage markers.
- the KC marker may be but is not limited to Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA-binding protein inhibitor ID-1 (ID1), and DNA-binding protein inhibitor ID-3 (ID3).
- LYVE1 Lymphatic Vessel Endothelial Hyaluronan Receptor 1
- ID1 DNA-binding protein inhibitor ID-1
- ID3 DNA-binding protein inhibitor ID-3
- iKC may express one or more KC markers.
- iKC may express combinations of KC markers.
- the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator may be but is not limited to Retinoid X Receptor Alpha (RXRA).
- the marker for liver regeneration and/or development may be but is not limited to Heparin Binding EGF Like Growth Factor (HBEGF) and Oncostatin M (OSM).
- HEGF Heparin Binding EGF Like Growth Factor
- OSM Oncostatin M
- iKC may express one or more markers for liver regeneration and/or development.
- iKC may express combinations of markers for liver regeneration and/or development.
- a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep).
- iKC iPSC-derived Kupffer cell
- iHep iPSC-derived hepatocyte
- the iKC and iHep of the combined cell population as described herein are derived from a single stem cell source. It will generally be understood that any somatic cell may be used to derive the stem cells of the present invention.
- the somatic cell used to derive the stem cells as used herein may include but are not limited to liver macrophages, Kupffer cells, fibroblasts, myoblasts, keratinocytes, melanocytes, hepatocytes, ⁇ -cells, dental pulp cells, blood cells and urine-derived renal epithelial cells.
- the stem cells as used herein may include but are not limited to human, non-human primate, murine and avian stem cells. It will be appreciated by a person skilled in the art that by obtaining both iHep and iKC from a single stem cell source, both iHep and iKC are thus, derived from the same subject. As such, iHep and iKC may be donor-matched.
- the iKC and iHep are derived from the single stem cell source of human IMR90- iPSCs.
- the combined cell population as described herein is for use as a model of a disease.
- the disease may be but is not limited to liver injury, drug- induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver.
- DILI drug- induced liver injury
- iPSC-derived macrophage iMac
- iHep iPSC-derived hepatocyte
- iKC induced pluripotent stem cell
- the presence or absence of a marker or the level of a marker may be detected or measured using conventional means in the art.
- the detection or measurement of the marker be an absolute measurement or a relative measurement.
- An absolute measurement of the expression of a marker may be determined by the presence or absence of said marker, or a characteristic of said marker, such as a concentration.
- a relative measurement of a marker may be obtained by comparing a level of expression or characteristic of said marker with a reference to determine a relative expression level of said marker, or relative concentration of said marker.
- the reference control may be but is not limited to an untreated combined cell population comprising an iKC, a combined cell population comprising an iKC generated from other methods and a primary KC.
- the agent may be but is not limited to a drug, a prodrug, a toxicant, a virus, a chimeric antigen receptor (CAR) T-cell, a protein, a phosphomimetic, a peptide, an antibody, an antibody-drug conjugate, a recombinant DNA, a short hairpin RNA, a microRNA, a short-interfering RNA, an agro-/environmental toxin, food, a consumer and cosmetic product.
- CAR chimeric antigen receptor
- the agent is a hepatotoxic drug.
- the hepatotoxic drug may be but is not limited to diclofenac (DIC), sulindac (SLD) leflunomide (LFM); amodiaquine (AQ), lamotrigine (LTG), allopurinol, carbamazepine, celecoxib, clavulanate, deferasirox, erythromycin, flucloxacillin, nevirapine, phenytoin, posaconazole, propylthiouracil, rifampicin, roxithromycin, sulfasalazine, dihydralazine, halothane, methyldopa, minocycline, nitrofurantoin.
- DIC diclofenac
- SLD sulindac
- LFM leflunomide
- AQ amodiaquine
- LTG lamotrigine
- allopurinol carbamazepine
- Markers include but are not limited to genes or proteins. As described herein, the marker may be but is not limited to an inflammatory mediator, a growth factor and a reactive oxygen species.
- the inflammatory mediator is a cytokine.
- the cytokine may be but is not limited to interferon- ⁇ (IFN- ⁇ ), interleukin (IL) IL-1 ⁇ , IL-6, IL-10, IL-12, IL-17, IL-18 and tumor necrosis factor- ⁇ (TNF- ⁇ ).
- the inflammatory mediator is a chemokine.
- the chemokine may be but is not limited to CCL2, CCL3, CCL4, CCL5, CCL11.
- the marker is a growth factor.
- the growth factor may be but is not limited to platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGF- ⁇ 1), growth factors from the tumor-necrosis factor (TNF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP) families.
- the marker is a reactive oxygen species.
- the reactive oxygen species may be but is not limited to superoxide anion (O 2 -), hydrogen peroxide (H 2 O 2 ), hydroxyl radical and singlet oxygen.
- a method of treating a liver disease in a subject in need thereof wherein an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein is to be administered to said subject, wherein the disease may be but is not limited to liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver.
- DILI drug-induced liver injury
- iPSC induced pluripotent stem cell
- iKC iPSC-derived Kupffer cell
- iHep iPSC-derived hepatocyte
- DILI drug-induced liver injury
- iPSC induced pluripotent stem cell
- iKC iPSC-derived Kupffer cell
- iHep iPSC-derived hepatocyte
- IMR90-iPSCs were differentiated into iPSC-hepatocytes (iHeps) as previously described by Cai et al., (2015). Briefly, the iPSCs were cultured to 80% confluency, then made into single cells using Cell Dissociation Buffer (Gibco, 13151014) and seeded at 1.5 x 10 5 cells/cm 2 on the desired well plate format (i.e. 1.5 x 10 6 cells for a 6 well plate) and placed under hypoxic conditions (5% O 2 and 5% CO 2 ). Growth factors and media used starting from the next day to day 20 are detailed in Cai et al., (2015).
- iPSC-derived macrophages were either directly added to the iHeps or iHeps were harvested for seeding into smaller well formats for drug testing. The harvesting protocol has previously been detailed in Tasnim et al., (2016).
- iPSC-derived macrophages were either directly added to the iHeps or iHeps were harvested for seeding into smaller well formats for drug testing. The harvesting protocol has previously been detailed in Tasnim et al., (2016).
- IMR90-iPSCs were differentiated into iMacs as previously described by Takata et al., (2017). Briefly, the iPSCs were cultured to 80% confluency, then passaged using ReLESR.
- the passage conditions were optimised to result in roughly 1 x 10 5 cells in each well of a 6 well plate (Day -1).
- the cells were cultured in Stempro Media, consisting of Stempro-34 SFM (GIBCO, 10639-011), supplemented with 200 ug/mL Human Transferrin (Roche, 10-652-202-001), 1x L-Glut, 1x Pen/Strep, 0.5 mM Ascorbic Acid (Sigma, A4544) and 0.45mM MTG (Sigma, M6145).
- Differentiation Day 0 (5 ng/mL BMP4, 50 ng/mL VEGF, and 2 ⁇ M CHIR99021
- Differentiation Day 2 (5 ng/mL BMP4, 50 ng/mL VEGF, and 20 ng/mL FGF2)
- Differentiation Day 4 (15 ng/mL VEGF and 5 ng/mL FGF2)
- Differentiation Day 6 to 10 (10 ng/mL VEGF, 10 ng/mL FGF2, 50 ng/mL SCF, 30 ng/mL DKK-1 (RnD, 5439-DK), 10 ng/mL IL-6 (RnD, 206-IL), and 20 ng/mL IL-3
- Differentiation Day 12 and 14 (10 ng/mL FGF2, 50 ng/mL SCF, 10 ng/mL IL-6, and 20 ng/mL IL-3).
- the cells were cultured in 75% IMDM with GlutaMAX TM (GIBCO, 31980-030), 25% F12 (GIBCO, 11765-047), 1x N2 supplement (GIBCO, 17502- 048), 1x B27 Supplement (GIBCO, 17504-001), 0.05% BSA (GE Healthcare, SH30574) and 1x Pen/Strep, supplemented with 50ng/ml of CSF-1 (RnD, 216-MC), with a full media change every 3 days.
- the cells were kept in a hypoxic incubator (5% O2 and 5% CO2), before being transferred to a standard cell culture incubator for the next 18 days.
- PBMCs peripheral blood monocytes
- 1 x 10 6 CD14+ cells were then seeded per well of a 6 well plate in RPMI 1640 (Hyclone, SH30027.01) with 10% FBS (Biowest, S1810-500), 1x Pen/Strep, 1x Sodium Pyruvate, 1x NEAA and 1x L-Glut with 50ng/ml CSF-1 and cultured for 7 days. The purity of the monocyte-derived macrophages was then determined by flow cytometry.
- CSF-1 50ng/ml of CSF-1 was added to each well.
- the cells were cultured for 7 days, with a half-media change (2ml) on Day 4 consisting of the same media as described above with 100ng/ml of CSF-1, resulting in a final concentration of 50ng/ml CSF-1 in the well.
- the cells were collected by digesting with Accutase (StemCell, 07920) for flow cytometry, RNAseq analysis and qPCR.
- the number of iHeps and iMacs were downscaled to 96-well plates while maintaining the same iHep:iMac ratio (2.5:1).
- Flow cytometry Standard staining procedures were used to prepare the cells for flow cytometry analysis. Briefly, cells were dissociated into single cells using the different methods described above for the various tissues, before being incubated with 100 ⁇ l of antibody containing FACS buffer (1% BSA and 4mM EDTA in PBS) per 5 million cells for 20 minutes at 4°C. The cell suspension was then washed with 5ml of FACS buffer, centrifuged at 400g, and the supernatant was removed. The cells were finally resuspended in PBS containing 3uM DAPI (Invitrogen, D1306). Data was acquired by LSRII (BD Bioscience) and analyzed by Flow Jo (Tree Star, Inc.).
- cells were sorted using FACS Aria II (BD Bioscience) or FACS Aria III (BD Bioscience).
- the following antibodies were used: FITC-conjugated anti- human CD14 (Biolegend, 325604), APC/Cy7-conjugated anti-human CD45 (Biolegend, 368516), PE-conjugated anti-human CD163 (R&D Systems, FAB1607P-100), Alexa Fluor 647-conjugated anti-human CX3CR1 (Biolegend, 341608, PE/Cy7-conjugated anti-human CD11b (eBioscience, 25-0118-42).
- cDNA libraries were prepared using 2ng of total RNA and 1 ⁇ l of a 1:50,000 dilution of Ambion ERCC RNA Spike-in Controls (Thermofisher, 4456740) with the following modifications: 1. Use of 20mM TSO, 2. Use of 250pg of cDNA with 1/5 reaction of Nextera XT kit (Illumina, FC-131).
- RNA extracted using RNeasy Plus Micro-kit (Qiagen, 74034) was quantified using a NanoDropTM ND-1000 Spectrophotometer and converted to cDNA using iScript cDNA synthesis kit (Bio-Rad Laboratories, 1708890).
- qPCR was performed in 7000 Fast Real-Time PCR System (Applied Biosystems, Foster City, USA) with FastStart Universal SYBR Green Master (Rox) (Roche, 04913 850 001) and primers from GeneCopoeia, Inc. (Rockville, MD, USA).
- Gyceraldehyde-3-phosphate dehydrogenase served as internal control. Accession numbers of tested genes are listed in Table 1. [00105] Table 1. Accession numbers of tested genes.
- Target Gene Gene Name Accession GAPDH glyceraldehyde-3-phosphate dehydrogenase NM_001256799.2 AFP Alpha fetoprotein NM_000295 AAT Alpha-1 antitrypsin NM_001134 ASGPR Asialoglycoprotein Receptor NM_001671 ALB albumin NM_000477.3 CYP1A2 Cytochrome P4501A2 NM_000761.5 CYP3A4 Cytochrome P4503A4 NM_017460.5 CYP2B6 Cytochrome P4502B6 NM_000767.4 CYP2C9 Cytochrome P4502C9 NM_000771.3 UGT1A3 UDP-glucuroosyltransferase 1A3 NM
- cytokine production from dosed cells was normalized with the viability of cells measured from the same well. This ensures that changes in cytokines are not due to changes in cell numbers that might arise upon drug treatment. The normalized cytokine level was expressed as percentage of DMSO+LPS which allowed better comparison between different batches of experiments.
- Cell viability assay [00109] Cell viability was examined with AlamarBlue TM cell viability assay (Thermo Fisher Scientific Inc., Dal1025) according to manufacturer’s instructions. Briefly, AlamarBlue was diluted 10-fold using PBS containing 2 mg/mL of glucose and this working solution was added to the cells and incubated for 1 hour.
- Hepatocytes are high in metabolically activity and often require frequent media change for replenishment of nutrients and removal of waste.
- expression of key hepatic markers was assessed when media was changed every other day, every two days or every three days and compared to a daily media change (Figure 2).
- Example 2 Co-culture with iHeps imparts KC-like identity to iMacs [00120]
- PCA analysis showed that the co-iMacs clustered much tighter together, while iMacs that were cultured alone or in hepatocyte conditioned media (cond-iMac) were much more scattered (Figure 3A). This suggests that co-culturing iMacs in direct contact with iHeps helps maintain the identity of the iMacs better, mirroring how ex-vivo resident tissue macrophages (RTMs) rapidly lose their identity when removed from their tissue environment.
- RTMs ex-vivo resident tissue macrophages
- Day 7 co-iMacs upregulated the angiogenic Angiopoietin-like 4 (ANGPTL4), matching the angiogenic signature observed in the Day 7 co-iHeps.
- ANGPTL4 angiogenic Angiopoietin-like 4
- Table 2 Ingenuity pathway analysis revealed that the top pathway in Day 7 co- iMacs is the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway (Table 2), a key regulator of Kupffer cell identity, while the top pathway in Day 0 iMacs is the axonal guidance pathway, consisting of chemokines like C-X-C Motif Chemokine Ligand 12 (CXCL12) and C-X-C Motif Chemokine Receptor 4 (CXCR4), metalloproteases like ADAM Metallopeptidase With Thrombospondin Type 1 Motif 15 (ADAMTS15), and se
- iMacs cultured in direct co-culture with iHeps may be different from iMacs cultured in PHCM. Comparing the DEGs between Day 7 cond-iMacs and Day 7 co- iMacs, the Day 7 cond-iMacs upregulated immune-related genes such as Toll-Like Receptor 4 (TLR4) and CPA3 while the Day 7 co-iMacs more highly expressed tissue residency-related Fc Gamma Receptor IIIa (FCGR3A) ( Figure 3E).
- TLR4 Toll-Like Receptor 4
- CPA3 Fc Gamma Receptor IIIa
- Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA-binding protein inhibitor ID-1 (ID1) and DNA-binding protein inhibitor ID-3 (ID3), which are important markers of KC identity, were all upregulated in the co-iMacs but not in the cond-iMacs ( Figure 3G).
- Retinoid X Receptor Alpha (RXRA), the obligate binding partner of LXR, was also upregulated in only the co-iMacs.
- HBEGF Heparin Binding EGF Like Growth Factor
- OSM Oncostatin M
- Example 3 Gene expression confirms KC-like identity of iMacs and maturation of iHeps in co-culture
- the observations from the RNA sequencing analysis were confirmed by analysing gene expression of macrophage and KC-specific markers in Day 3 co-iMacs and Day 7 co- iMacs.
- Macrophage markers CD68, CD163, CD11b, CD32 and CD14 were all upregulated at Day 3 and Day 7 by 1.8 to 7.6 fold (Figure 4A; top panel) compared to iMac mono-culture control.
- KC-specific markers ID1 and ID3 were upregulated by 3.8 fold and 3.9 fold respectively at Day 3 and by 6.3 fold and 6.5 fold respectively at Day 7 ( Figure 4A; bottom panel).
- GST1A2 Glutathione-S transferase1A2
- MRP2 Multidrug Resistance Associated Protein 2
- co-culture with iMacs improved expression of several hepatic marker genes including ALB, ⁇ -1 antitrypsin (AAT), cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C9, CYP2B6) and UDP-glucuronosyltransferases (UGT1A3) by 1.8-53.1 fold at Day 3 and Day 7 of co-culture ( Figure 4C).
- AFP a marker that is expressed at high levels in fetal hepatocytes and increases with hepatocyte maturation, had 37% lower expression at Day 3 and 37% lower expression in Day 7 iHeps as compared to Day 0 iHeps ( Figure 4C). This is consistent with RNA sequencing data that showed a downregulation of AFP. [00133] Overall, the gene expression data confirms the RNA sequencing analysis findings that culturing iMacs with iHeps imparts KC-like phenotype in iMacs and supports maturation and function of the iHeps.
- Example 4 Co-culture model accurately mimics clinical/in-vivo immune responses of drugs [00136]
- a group of 7 drugs was carefully selected based on the following criteria: 1) confirmed reports of immune/inflammation-associated effects according to 3 databases; 2) available clinical data, or in vivo responses if the former is unavailable; and 3) known Cmax (maximum serum concentration of drug) to guide the concentration of drug used in in the in vitro model (Drug concentrations used in the system was no more than 20-fold of its Cmax. Details of selected drugs are summarized in Table 6.
- DIC diclofenac
- SLD sulindac
- LFM lamotrigine
- PEN penicillin
- PZA pyrazinamide
- DIC, SLD and LFM have been reported to cause a decrease in interleukin-6 (IL-6); whereas AQ and LTG have been reported to cause an increase in IL-6 in patients with drug-induced liver injury.
- PEN and PZA were selected as negative controls as no immune-mediated effects of these drugs have been reported.
- the co-culture model could correctly recapitulate IL-6 decrease in DIC, SLD and LFM, IL-6 increase in AQ and LTG and no change in IL-6 in PEN and PZA-treated samples (Figure 5).
- KCs have been known to release mediators that are early features of inflammatory responses. They are activated in response to inflammatory stimuli such as bacterial lipopolysaccharide (LPS) that can damage the liver at large doses in a KC- dependent manner. At smaller doses, LPS activates KCs (without causing liver injury) but sensitizes the liver to a variety of other xenobiotics. In the model, when the co-culture was co-treated with paradigm hepatotoxicants and LPS, drug-dose-dependent changes in cytokine production were observed, suggesting that the system can indeed mimic physiological responses.
- inflammatory stimuli such as bacterial lipopolysaccharide (LPS) that can damage the liver at large doses in a KC- dependent manner.
- LPS bacterial lipopolysaccharide
- LPS activates KCs (without causing liver injury) but sensitizes the liver to a variety of other xenobiotics.
- LPS bacterial lipopolys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present disclosure relates to methods of generating induced pluripotent stem cell (iPSC)-derived Kupffer cells (iKCs), where the method comprises contacting iPSC-derived macrophages with iPSC-derived hepatocytes (iHeps), kits for generating iKCs, iKCs derived by the methods as described herein, combined cell populations comprising iKCs and iHeps. Methods of detecting immune-mediated responses to an agent using the iKCs, methods of treating a disease using the iKCs or the combined cell population comprising iKCs and iHeps are also described herein.
Description
CO-CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELL (HIPSC) – DERIVED MACROPHAGES AND HEPATOCYTES FOR GENERATION OF HIPSC-KUPFFER CELLS FIELD OF THE INVENTION [0001] The invention relates to a method of generating Kupffer cells from pluripotent stem cells. Specifically, the invention relates to a method of co-culturing pluripotent stem cell derived macrophages and pluripotent stem cell derived hepatocytes to generate Kupffer cells. BACKGROUND OF THE INVENTION [0002] Liver-resident Kupffer cells (KCs) form a major population of hepatic macrophages. They play key roles in hepatotoxicity, liver injury and repxyxy KCs are involved in maintaining liver homeostasis and contributing to progression of hepatic injury in the absence and presence of external stimuli respectively. For example, stimuli from foreign particles/bacterial endotoxins are endocytosed by KCs; consecutively, cell damage or soluble stress signals leads to KC activation and production of cell signaling and stress pathway modulators, including reactive oxygen species and cytokines. KC activation also regulates parenchymal hepatic and non-parenchymal cell death by apoptosis and metabolic activity of hepatocytes. Such crosstalk between liver parenchymal cells (hepatocytes) and non- parenchymal modulators (KCs) is critical in modelling liver injury, especially immune- mediated drug-induced responses. [0003] Animal models have been used to model immune-mediated liver injury. However, these animal models have often not been able to recapitulate clinical findings. Consistent liver injury was not observed upon treatment with drugs known to cause immune response in humans, even at high doses. In cases where injury was observed, the characteristics were different from humans and possibly manifested through different mechanisms. Such interspecies variations, contradictory findings as well as cost and ethical issues have spurred the development of in vitro models to supplement in vivo animal models. [0004] In vitro models, possibly due to the lack of appropriate human immune cell sources, have focused on soluble factor-driven single hepatocyte cultures in combination with inflammatory mediators or animal cell co-cultures. However, mono-cultures lack cell-cell interactions and animal in vitro models often fail to recapitulate in vivo and clinical findings. Another main challenge in studying human KCs in in vitro models is the cell source. The
source of commercial primary human KCs (PhKCs) is limited and costly and high donor-to- donor variability is often observed. Alternative human cell sources include THP-1 cells and peripheral monocyte-derived macrophages; however their cytokine profiles are dramatically different from human KCs, and they lack liver-specific imprinting. Induced pluripotent stem cell (iPSC) derived KCs (iKCs) have been developed from using conditioned media from primary hepatocytes (PHCM) to drive iPSC-derived macrophages (iMacs) towards iKCs. Although these iKCs functionally resembled PhKCs, PHCM is expensive due to the cost of primary cell culture and exhibit differences depending on donor variability of primary hepatocytes. [0005] Therefore, there is a need to provide a method to generate Kupffer cells that overcomes, or at least ameliorates, one or more of the disadvantages described above to predict drug-induced cytokine responses and investigate new drugs that cause cytokine imbalance. SUMMARY [0006] In one aspect, provided herein is a method of generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising the steps of: (a) providing an iPSC- derived macrophage (iMac); (b) providing an iPSC-derived hepatocyte (iHep); (c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate the iKC. [0007] In another aspect, provided herein is a kit when used in the method as described herein, for generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising: (a) an iPSC-derived macrophage (iMac); (b) an iPSC-derived hepatocyte (iHep); and (c) a premixed cell culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAXTM and about 30mM HEPES buffer with instructions for use. [0008] In another aspect, provided herein is an induced pluripotent stem cell (iPSC)- derived Kupffer cell (iKC) obtained by the method as described herein. [0009] In another aspect, provided herein is a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep). [0010] In another aspect, provided herein is a method of detecting an immune-mediated response to an agent comprising the steps of: (a) providing an iPSC-derived macrophage (iMac); (b) providing an iPSC-derived hepatocyte (iHep); (c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate a combined cell population comprising an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC); (d)
contacting and incubating the combined cell population from step (c) with the agent; (e) detecting the presence or absence of a marker or measuring a level of said marker to detect the immune-mediated response to the agent. [0011] In another aspect, provided herein is a method of treating a liver disease in a subject in need thereof, wherein an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein is to be administered to said subject, wherein the disease is selected from the group consisting of: liver injury, drug- induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver. [0012] In another aspect, provided herein is a use of an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein in the manufacture of a medicament for the treatment of a liver disease selected from the group consisting of: liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver. [0013] In yet another aspect, provided herein is an induced pluripotent stem cell (iPSC)- derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein, for use in treating a liver disease selected from the group consisting of: liver injury, drug- induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver. [0014] In yet another aspect, provided herein is an induced pluripotent stem cell (iPSC)- derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein, for use in therapy.
DEFINITIONS [0015] As used herein, the term “induced pluripotent stem cells” or “iPSCs” refers to pluripotent stem cells that are derived from a non-pluripotent cell such as a somatic cell that has been reprogrammed to a pluripotent state. The process of generating iPSCs typically involves introducing products of specific sets of pluripotency-associated genes, or "reprogramming factors". The somatic cells used to derive the stem cells may include but are not limited to liver macrophages, Kupffer cells, fibroblasts, myoblasts, keratinocytes, melanocytes, hepatocytes, β-cells, dental pulp cells, blood cells and urine-derived renal epithelial cells. The stem cells as used herein may include but are not limited to human, non- human primate, murine and avian stem cells. [0016] As used herein, the term “differentiate” refers to the developmental process by which a cell has progressed further down a developmental pathway than its immediate precursor cell. A differentiated cell is a cell of a more specialized cell type derived from a cell of a less specialized cell type in a cellular differentiation process. A differentiated cell is one that has taken on a more committed position within the lineage of the cell. [0017] As used herein, the term “macrophage” refers to a mononuclear phagocyte that recognizes, ingests and degrades cellular debris, microbes or any other foreign materials in a process termed phagocytosis. Macrophages are the most abundant liver immune cells and play a key role in tissue homeostasis and immunity. Embryonically-derived Kupffer cells (KCs) are the main population of macrophages of the liver and express liver specific markers. Monocyte-derived macrophages (MoMϕs) exist in the liver but represent a minor population of macrophages that increase during inflammation. [0018] As used herein, the term “hepatocyte” refers to a primary liver cell or hepatic parenchymal cell that is involved in metabolic processes. Hepatocytes comprise up to 80% of the total cell population of the human liver. Some of the metabolic processes that hepatocytes are involved in include carbohydrate metabolism, for example glycogen synthesis, glycolysis, and drug metabolism. [0019] As used herein, the term “Kupffer cells” refers to the self-renewing, resident and principally non-migratory phagocyte population in the liver. Kupffer cells originate from yolk sac-derived specific progenitor cells that seed the liver during embryogenesis. Kupffer cells are innate immune cells in the liver. Some of the important roles that Kupffer cells are involved in include scavenging for foreign materials and phagocytosis of cellular debris,
foreign material or pathogens and maintenance of iron homeostasis via phagocytosis of red blood cells and recycling of iron. As such, they are regarded as critical sentinels that ensure liver homeostasis and eliminate antibodies, debris or dead cells. In healthy livers, Kupffer cells are exclusively located in the intravascular compartment (mainly within the hepatic sinusoids). [0020] As used herein, the term “iMac” refers to induced pluripotent stem cell (iPSC)- derived macrophage. iMacs are derived by differentiation of iPSCs according to the method described in Takata et al., (2017). Specifically, the iPSCs were cultured to 80% confluency, then passaged using ReLESR. As ReLESR releases the cells as small cell clumps, the passage conditions were optimised to result in roughly 1 x 105 cells in each well of a 6 well plate (Day -1). Starting from the next day (Day 0) to day 16, the cells were cultured in Stempro Media, consisting of Stempro-34 SFM (GIBCO, 10639-011), supplemented with 200 ug/mL Human Transferrin (Roche, 10-652-202-001), 1x L-Glut, 1x Pen/Strep, 0.5 mM Ascorbic Acid (Sigma, A4544) and 0.45mM MTG (Sigma, M6145). A full media change was done every other day for the next 16 days, supplemented with the following cytokines: Differentiation Day 0 (5 ng/mL BMP4, 50 ng/mL VEGF, and 2 µM CHIR99021), Differentiation Day 2 (5 ng/mL BMP4, 50 ng/mL VEGF, and 20 ng/mL FGF2), Differentiation Day 4 (15 ng/mL VEGF and 5 ng/mL FGF2), Differentiation Day 6 to 10 (10 ng/mL VEGF, 10 ng/mL FGF2, 50 ng/mL SCF, 30 ng/mL DKK-1 (RnD, 5439-DK), 10 ng/mL IL-6 (RnD, 206-IL), and 20 ng/mL IL-3), Differentiation Day 12 and 14 (10 ng/mL FGF2, 50 ng/mL SCF, 10 ng/mL IL-6, and 20 ng/mL IL-3). From day 16, the cells were cultured in 75% IMDM with GlutaMAXTM (GIBCO, 31980-030), 25% F12 (GIBCO, 11765- 047), 1x N2 supplement (GIBCO, 17502-048), 1x B27 Supplement (GIBCO, 17504-001), 0.05% BSA (GE Healthcare, SH30574) and 1x Pen/Strep, supplemented with 50ng/ml of CSF-1 (RnD, 216-MC), with a full media change every 3 days. In addition, for the first 8 days of differentiation, the cells were kept in a hypoxic incubator (5% O2 and 5% C O2), before being transferred to a standard cell culture incubator for the next 18 days. After transfer to a standard cell culture incubator, floating cells were collected every media change and resuspended back into the culture to retain the hematopoietic progenitors. After 26 days, the floating cells were collected and the purity of the iMacs was determined by flow cytometry.
[0021] As used herein, the term “iHep” refers to an induced pluripotent stem cell (iPSC)- derived hepatocyte. According to the method as described in Cai et al., (2015), iHeps are derived by differentiation of iPSCs. Specifically, the iPSCs were cultured to 80% confluency, then made into single cells using Cell Dissociation Buffer (Gibco, 13151014) and seeded at 1.5 x 105 cells/cm2 on the desired well plate format (i.e.1.5 x 106 cells for a 6 well plate) and placed under hypoxic conditions (5% O2 and 5% CO2). The cells are seeded onto appropriate plate and cultured overnight under the hypoxic conditions as described herein. The day after the culture overnight is referred to as differentiation day 1. On differentiation day 1, culture medium was removed and replaced with RPMI/B-27 (minus Insulin) (Invitrogen/Gibco) supplemented with 100 ng/ml Activin A (R&D systems), 10 ng/mL BMP4 (Peprotech) and 20 ng/mL FGF2 (Invitrogen). Culture medium was changed daily and cultured for 2 days at 37°C in ambient O2/5% CO2. On differentiation days 3 to 5, culture medium was changed to RPMI/B-27 (minus Insulin) supplemented with 100 ng/ml Activin A and continued to culture for an additional 3 days at 37°C in ambient O2/5% CO2 with daily medium changes. On differentiation day 6, culture medium was changed to RPMI/B27 (complete with Insulin) supplemented with 20 ng/ml BMP-4 and 10 ng/ml FGF2. Culture was incubated for 5 days at 37°C in 4% O2/5% CO2 and culture medium was replaced daily for a total of 5 days. On differentiation day 11, culture medium was changed to RPMI/B27 (complete with Insulin) supplemented with 20 ng/ml Hepatocyte Growth Factor (HGF) (Peprotech). Culture was incubated for 5 days at 37°C in 4% O2/5% CO2 and medium was replaced daily. On differentiation day 16, culture medium was changed to Clonetics® HCM™ Hepatocyte Culture Medium (Lonza CC-3198) containing ‘Singlequots’ (see HCM medium below) omitting the EGF from the Lonza HCM bullet kit. In addition to the kit supplements, 20 ng/ml Oncostatin-M (R&D Systems) was added. Culture was incubated for 5 days at 37°C in ambient O2/5% CO2 and culture medium was replaced daily. After 20 days of differentiation, iPSC-derived macrophages (iMacs) were directly added to the iHeps. [0022] As used herein, the term “subject” or “patient” refers to all animals classified as mammals and includes but is not limited to primates, humans, cows, horses, pigs, sheep, goats, dogs, cats, or rodents. Preferably, the subject is a human man or woman of any age or race. [0023] As used herein, the term “treatment”, refers to any type of therapy, which aims at terminating, preventing, ameliorating or reducing the susceptibility to a clinical condition as
described herein. The effect may be prophylactic in terms of completely or partially preventing a disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse effect attributable to the disorder. As such, “treatment” includes preventing the disorder from occurring or recurring in a subject, inhibiting the disorder, such as arresting its development, stopping or terminating the disorder or at least symptoms associated therewith, so that the host no longer suffers from the disorder or its symptoms, such as causing regression of the disorder or its symptoms, for example, by restoring or repairing a lost, missing or defective function, or stimulating an inefficient process, or relieving, alleviating, or ameliorating the disorder, or symptoms associated with the disorder. [0024] As used herein, the term “about”, is used in the context of, but not limited to, concentrations of components and percentages of compounds. Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub- ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range. BRIEF DESCRIPTION OF THE DRAWINGS [0025] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which: [0026] Figure 1 depicts the model development and shows a schematic of the experimental layout. [0027] Figure 2 shows the assessment of hepatocyte performance as a function of media supplementation. Figure 2A shows gene expression of hepatic markers upon treatment with media supplemented 2X and media changed performed every day, every other day or every two days. Figure 2B shows hepatic marker expression with 2X media supplementation and
2X media volume to account for the infrequent media change. Gene expression was compared as fold change to standard hepatocyte culture conditions (daily media change with 1X supplement and standard media volume). Increasing supplements alone could maintain the expression of ALB (albumin), AAT (alpha-1-antitrypsin), cytochrome P450 (CYP)- 1A2, 3A4, 2B6 and UDP-glucuronosyltransferase (UGT)1A3, but not CYP2C19 (36 - 68% decrease), glutathione S-transferase (GST)A2 (35-66% decrease) and multidrug resistance protein-2 (MRP2; 7 to 18% decrease) (Figure 2A). In contrast, combining the increase in supplements with increase in culture volume resulted in maintenance of all hepatic markers (Figure 2B). Figure 2C shows albumin and urea production when hepatocytes were harvested and reseeded for experimental set up compared to unharvested hepatocytes (in situ), demonstrating that hepatocytes harvesting does not compromise cell functionality. [0028] Figure 3 shows the effects of iHeps on iMacs. Figure 3A shows the Principal Component Analysis of bulk RNAseq data from Day 0 iMacs, Day 3 co-iMacs, Day 7 co- iMacs, Day 7 iMacs and Day 7 cond-iMacs. Figure 3B shows the heatmap showing the top 5 differentially and uniquely expressed genes from culturing iMacs alone, with conditioned media (cond-iMacs) and after co-culture with iHepatocytes (Day 7 co-iMacs). Figure 3C shows the volcano plot showing differentially-expressed genes between Day 0 iMacs and Day 7 co-iMacs. Figure 3D shows the differentially expressed upregulated pathways between Day 0 iMacs and Day 7 co-iMacs. Figure 3E shows the volcano plot showing differentially-expressed genes between Day 7 cond-iMacs and Day 7 co-iMacs. Figure 3F shows the differentially expressed upregulated pathways between Day 7 cond-iMacs and Day 7 co-iMacs. Figure 3G shows the Gene expression levels of LYVE1, ID1, ID3, RXRA, HBEGF and OSM in Day 0 iMacs, Day 3 co-iMacs, Day 7 co-iMacs, Day 7 iMacs and Day 7 cond-iMacs. [0029] Figure 4 shows the gene expression of iMac and iHep markers in co-cultures. Figure 4A shows the expression of macrophage markers (top panel) and KC-specific markers (bottom panel) on day 3 and day 7 of co-culture. Figure 4B shows the expression of macrophage markers (top panel) and KC-specific markers (bottom panel) on day 7 of co- culture compared to iMac cultured in PHCM. Figure 4C shows the expression of hepatic markers on day 3 and day 7 of co-culture. * p<0.05. [0030] Figure 5 shows the changes in IL-6 level upon treatment with 7 paradigm compounds when iMac-derived KCs were used. Cytokine production was assessed in iMac-
derived iKC and iHep co-culture treated with the drug stated in the plot title. Data is expressed as the percentage of the LPS-treated vehicle control. Error bars represented S.D., n=3. One-way ANOVA was applied. *p<0.05, **p<0.01 between treatment and vehicle control. [0031] Figure 6 shows the changes in IL-6 level upon treatment with 7 paradigm compounds without iMac-derived KCs. Cytokine production was assessed in blood monocyte-derived macrophages and iHep co-culture treated with the drug stated in the plot title. Data is expressed as the percentage of the LPS-treated vehicle control. Error bars represented S.D., n=3. One-way ANOVA was applied. *p<0.05, **p<0.01 between treatment and vehicle control. DETAILED DESCRIPTION OF THE PRESENT INVENTION [0032] In a first aspect the present invention refers to a method of generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising the steps of (a) providing an iPSC-derived macrophage (iMac); (b) providing an iPSC-derived hepatocyte (iHep); (c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate the iKC. [0033] In some examples, the iKC may demonstrate one or more biological characteristics or phenotypes of a Kupffer cell (KC). In some examples, the biological characteristic of a KC may be an expression of a macrophage marker, an expression of a KC marker, an expression of a Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signaling pathway regulator, an expression of a marker for liver regeneration and/or development, or combinations thereof. It will be appreciated by a person skilled in the art that where the iKC demonstrates one or more biological characteristics of a KC, these can be one or more biological characteristics from different groups of markers. For example, the iKC may express one or more macrophage markers and one or more KC markers. In another example, the iKC may express one or more macrophage markers and one or more LXR/RXR signal pathway regulators. In another example, the iKC may express one or more macrophage markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more KC markers and one or more LXR/RXR signal pathway regulators. In another example, the IKC may express one or more KC markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more
LXR/RXR signal pathway regulators and one or more markers for liver regeneration and/or development. [0034] In some examples, the macrophage marker may be but is not limited to CD68, CD163, CD11b, CD32 and CD14. It will be appreciated by a person skilled in the art that iKC may express one or more macrophage markers. In some examples, a person skilled in the art will understand that iKC may express combinations of macrophage markers. [0035] In some examples, the KC marker may be but is not limited to Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA-binding protein inhibitor ID-1 (ID1), and DNA-binding protein inhibitor ID-3 (ID3). It will be appreciated by a person skilled in the art that iKC may express one or more KC markers. In some examples, a person skilled in the art will understand that iKC may express combinations of KC markers. [0036] In one example, the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator may be but is not limited to Retinoid X Receptor Alpha (RXRA). [0037] In some examples, the marker for liver regeneration and/or development may be but is not limited to Heparin Binding EGF Like Growth Factor (HBEGF) and Oncostatin M (OSM). It will be appreciated by a person skilled in the art that iKC may express one or more markers for liver regeneration and/or development. In some examples, a person skilled in the art will understand that iKC may express combinations of markers for liver regeneration and/or development. [0038] In some examples, the number of iHeps to iMacs may be cultured at a ratio of about 1:1: to about 10:1. For example, the ratio of iHeps to iMacs may be about 1:1, about 1.5:1, about 2:1, about 2.5:1, about 3:1, about 3.5:1, about 4:1, about 4.5:1, about 5:1, about 5.5:1, about 6:1, about 6.5:1, about 7:1, about 7.5:1, about 8:1, about 8.5:1, about 9:1, about 9.5:1, about 10:1. In a preferred example, the ratio of iHeps to iMacs is about 2.5:1. [0039] In one example, the iHeps and iMacs may be incubated on a cell culture plate. The culture plate may be a 6-well plate, 12-well plate, 24-well plate, 48-well plate or 96-well plate. In another example, the iHeps and iMacs may be incubated on a culture dish. The culture dish may be a 35mm dish, 60mm dish, 100mm dish or 150mm culture dish. In another example, the iHeps and iMacs may be incubated in a culture flask. The culture flask may be a T25 flask, T75 flask, T175 flask or T225 flask.
[0040] The iHeps and iMacs of the present invention may be cultured in the presence of an extracellular matrix (ECM), for example, Matrigel. [0041] In one example, the iHeps and iMacs may be cultured on a 6-well plate. In one example, the iHeps and iMacs may be cultured on a Matrigel-coated 6-well plate or an extracellular matrix (ECM)-coated 6-well plate. [0042] In one example, the number of iHeps and iMacs cultured on a 6-well plate is about 5 x 105 and about 2 x 105 respectively. It will be appreciated by a person skilled in the art that the cell density of iHeps and iMacs to be cultured can be scaled proportionately based on the surface area of the culture vessel used. [0043] In one example, the total number of iHeps and iMacs cultured on a 6-well plate is up to 1.5 x 106. It will be appreciated by a person skilled in the art that the cell density of iHeps and iMacs to be cultured can be scaled proportionately based on the surface area of the culture vessel used. [0044] In some examples, the concentration of the Penicillin/Streptomycin in the culture medium may be between 0.1% and about 3%. For example, the concentration of the Penicillin/Streptomycin may be about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, and about 3.0%. In a preferred example, the concentration of Penicillin/Streptomycin is about 1.0%. [0045] In some examples, the concentration of the ITS in the culture medium may be between 0.1% and about 4%. For example, the concentration of the ITS may be about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, about 3.0%, about 3.1%, about 3.2%, about 3.3%, about 3.4%, about 3.5%, about 3.6%, about 3.7%, about 3.8%, about 3.9% and about 4.0%. In a preferred example, the concentration of ITS is about 2.0%. [0046] In some examples, the concentration of the GlutaMAXTM in the culture medium may be between 1mM and about 7mM. For example, the concentration of the GlutaMAXTM
may be about 1.0mM, about 1.1mM, about 1.2mM, about 1.3mM, about 1.4mM, about 1.5mM, about 1.6mM, about 1.7mM, about 1.8mM, about 1.9mM, about 2.0mM, about 2.1mM, about 2.2mM, about 2.3mM, about 2.4mM, about 2.5mM, about 2.6mM, about 2.7mM, about 2.8mM, about 2.9mM, about 3.0mM, about 3.1mM, about 3.2mM, about 3.3mM, about 3.4mM, about 3.5mM, about 3.6mM, about 3.7mM, about 3.8mM, about 3.9mM, about 4.0mM, about 4.1mM, about 4.2mM, about 4.3mM, about 4.4mM, about 4.5mM, about 4.6mM, about 4.7mM, about 4.8mM, about 4.9mM, about 5.0mM, about 5.1mM, about 5.2mM, about 5.3mM, about 5.4mM, about 5.5mM, about 5.6mM, about 5.7mM, about 5.8mM, about 5.9mM, about 6.0mM, about 6.1mM, about 6.2mM, about 6.3mM, about 6.4mM, about 6.5mM, about 6.6mM, about 6.7mM, about 6.8mM, about 6.9mM, and about 7.0mM. In a preferred example, the concentration of GlutaMAXTM is about 4.0mM. [0047] In some examples, the concentration of the HEPES buffer in the culture medium may be between 5mM and 50mM. For example, the concentration of the HEPES buffer may be about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM, about 20mM, about 21mM, about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM, about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, and about 50mM. In a preferred example, the concentration of HEPES buffer is about 30mM. [0048] In a preferred example, the iHep and iMac are incubated with culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAXTM and about 30mM HEPES buffer. [0049] In one example, the culture medium may contain CSF-1. [0050] In one example, the culture medium does not contain dexamethasone. [0051] In some examples, the concentration of the CSF-1 in the culture medium may be between 25ng/mL to 75ng/mL. For example, the concentration of the CSF-1 may be about 25ng/mL, about 26ng/mL, about 27ng/mL, about 28ng/mL, about 29ng/mL, about 30ng/mL, about 31ng/mL, about 32ng/mL, about 33ng/mL, about 34ng/mL, about 35ng/mL, about 36ng/mL, about 37ng/mL, about 38ng/mL, about 39ng/mL, about 40ng/mL, about 41ng/mL,
about 42ng/mL, about 43ng/mL, about 44ng/mL, about 45/mL, about 46ng/mL, about 47ng/mL, about 48ng/mL, about 49ng/mL, about 50ng/mL, about 51ng/mL, about 52ng/mL, about 53ng/mL, about 54ng/mL, about 55ng/mL, about 56ng/mL, about 57ng/mL, about 58ng/mL, about 59ng/mL, about 60ng/mL, about 61ng/mL, about 62ng/mL, about 63ng/mL, about 64ng/mL, about 65ng/mL, about 66ng/mL, about 67ng/mL, about 68ng/mL, about 69ng/mL, about 70ng/mL, about 71ng/mL, about 72ng/mL, about 73ng/mL, about 74ng/mL, and about 75ng/mL. In a preferred example, the concentration of CSF-1 is about 50ng/mL. [0052] In one example, the culture medium does not contain primary hepatocyte conditioned media. A person skilled in the art will understand that the primary hepatocyte conditioned media refers to culture media used in culturing primary hepatocytes. [0053] In some examples, the iPSCs may be human iPSCs. In one example, the iPSCs may be but is not limited to IMR90-F4, IMR90-iPSCs, Kyou-DXR0109B, PCi-ASI and PCi- CAU. [0054] In another example, the iPSC may be derived or reprogrammed from a somatic cell obtained from a subject or patient. [0055] In some examples, the volume of culture media per well of a 6-well plate may be between 2.0mL to 6.0mL. For example, the volume of culture media per well of a 6-well plate may be about 2.0mL, about 2.1mL, about 2.2mL, about 2.3mL, about 2.4mL, about 2.5mL, about 2.6mL, about 2.7mL, about 2.8mL, about 2.9mL, about 3.0mL, about 3.1mL, about 3.2mL, about 3.3mL, about 3.4mL, about 3.5mL, about 3.6mL, about 3.7mL, about 3.8mL, about 3.9mL, about 4.0mL, about 4.1mL, about 4.2mL, about 4.3mL, about 4.4mL, about 4.5mL, about 4.6mL, about 4.7mL, about 4.8mL, about 4.9mL, about 5.0mL, about 5.1mL, about 5.2mL, about 5.3mL, about 5.4mL, about 5.5mL, about 5.6mL, about 5.7mL, about 5.8mL, about 5.9mL and about 6.0mL. In a preferred example, the volume of culture media per well of a 6-well plate is 4.0mL. [0056] In some examples, the iHep and iMac may be cultured for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 days, wherein day 0 refers to the day iHep and iMac are in contact and cultured in a single culture vessel. In a preferred example, the iHep and iMac are cultured for 7 days. [0057] In some examples, about 2mL of culture media is aspirated from a well in the 6- well culture plate and replaced with about 2mL of newly prepared culture media of the same on or after day 4. It will be appreciated by a person skilled in the art that the volume of
culture media aspirated can be scaled proportionately based on the volumetric size of the culture vessel used. A person skilled in the art will understand to replace the aspirated culture media with an equal volume of freshly prepared culture media of the same. In one example, 2mL of culture media is aspirated from the 6-well culture plate and replaced with 2mL of newly prepared culture media of the same on day 4. [0058] In another aspect, provided herein is a kit when used in the method as described herein, for generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC), comprising: (a) an iPSC-derived macrophage (iMac); (b) an iPSC-derived hepatocyte (iHep); and (c) a premixed cell culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAXTM and about 30mM HEPES buffer with instructions for use. [0059] In another aspect, provided herein is an induced pluripotent stem cell (iPSC)- derived Kupffer cell (iKC) obtained by the method as described herein. [0060] In one example, the iKC may express higher levels of KC-specific markers compared to an iMac cultured in primary hepatocyte conditioned media. [0061] In some examples, the iKC may express one or more biological characteristics of a Kupffer cell (KC). In some examples, the biological characteristic of a KC may be an expression of a macrophage marker, an expression of a KC marker, an expression of a Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signaling pathway regulator, an expression of a marker for liver regeneration and/or development, or combinations thereof. It will be appreciated by a person skilled in the art that where the iKC demonstrates one or more biological characteristics of a KC, these can be one or more biological characteristics from different groups of markers. For example, the iKC may express one or more macrophage markers and one or more KC markers. In another example, the iKC may express one or more macrophage markers and one or more LXR/RXR signal pathway regulators. In another example, the iKC may express one or more macrophage markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more KC markers and one or more LXR/RXR signal pathway regulators. In another example, the IKC may express one or more KC markers and one or more markers for liver regeneration and/or development. In another example, the iKC may express one or more LXR/RXR signal pathway regulators and one or more markers for liver regeneration and/or development [0062] In some examples, the macrophage marker may be but is not limited to CD68, CD163, CD11b, CD32 and CD14. It will be appreciated by a person skilled in the art that
iKC may express one or more macrophage markers. In some examples, a person skilled in the art will understand that iKC may express combinations of macrophage markers. [0063] In some examples, the KC marker may be but is not limited to Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA-binding protein inhibitor ID-1 (ID1), and DNA-binding protein inhibitor ID-3 (ID3). It will be appreciated by a person skilled in the art that iKC may express one or more KC markers. In some examples, a person skilled in the art will understand that iKC may express combinations of KC markers. [0064] In one example, the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator may be but is not limited to Retinoid X Receptor Alpha (RXRA). [0065] In some examples, the marker for liver regeneration and/or development may be but is not limited to Heparin Binding EGF Like Growth Factor (HBEGF) and Oncostatin M (OSM). It will be appreciated by a person skilled in the art that iKC may express one or more markers for liver regeneration and/or development. In some examples, a person skilled in the art will understand that iKC may express combinations of markers for liver regeneration and/or development. [0066] In another aspect, provided herein is a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep). [0067] In one example, the iKC and iHep of the combined cell population as described herein are derived from a single stem cell source. It will generally be understood that any somatic cell may be used to derive the stem cells of the present invention. For example, the somatic cell used to derive the stem cells as used herein may include but are not limited to liver macrophages, Kupffer cells, fibroblasts, myoblasts, keratinocytes, melanocytes, hepatocytes, β-cells, dental pulp cells, blood cells and urine-derived renal epithelial cells. The stem cells as used herein may include but are not limited to human, non-human primate, murine and avian stem cells. It will be appreciated by a person skilled in the art that by obtaining both iHep and iKC from a single stem cell source, both iHep and iKC are thus, derived from the same subject. As such, iHep and iKC may be donor-matched. In a preferred example, the iKC and iHep are derived from the single stem cell source of human IMR90- iPSCs. [0068] In one example, the combined cell population as described herein is for use as a model of a disease. In one example, the disease may be but is not limited to liver injury, drug-
induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver. [0069] In another aspect, provided herein is the method of detecting an immune-mediated response to an agent comprising the steps of: (a) providing an iPSC-derived macrophage (iMac); (b) providing an iPSC-derived hepatocyte (iHep); (c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate a combined cell population comprising an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC); (d) contacting and incubating the combined cell population from step (c) with the agent; (e) detecting the presence or absence of a marker or measuring a level of said marker to detect the immune-mediated response to the agent. [0070] The presence or absence of a marker or the level of a marker may be detected or measured using conventional means in the art. [0071] As described herein, it would be understood by a person skilled in the art that the detection or measurement of the marker be an absolute measurement or a relative measurement. An absolute measurement of the expression of a marker may be determined by the presence or absence of said marker, or a characteristic of said marker, such as a concentration. A relative measurement of a marker may be obtained by comparing a level of expression or characteristic of said marker with a reference to determine a relative expression level of said marker, or relative concentration of said marker. The reference control may be but is not limited to an untreated combined cell population comprising an iKC, a combined cell population comprising an iKC generated from other methods and a primary KC. [0072] As described herein, the agent may be but is not limited to a drug, a prodrug, a toxicant, a virus, a chimeric antigen receptor (CAR) T-cell, a protein, a phosphomimetic, a peptide, an antibody, an antibody-drug conjugate, a recombinant DNA, a short hairpin RNA, a microRNA, a short-interfering RNA, an agro-/environmental toxin, food, a consumer and cosmetic product. [0073] In one example, the agent is a hepatotoxic drug. The hepatotoxic drug may be but is not limited to diclofenac (DIC), sulindac (SLD) leflunomide (LFM); amodiaquine (AQ), lamotrigine (LTG), allopurinol, carbamazepine, celecoxib, clavulanate, deferasirox, erythromycin, flucloxacillin, nevirapine, phenytoin, posaconazole, propylthiouracil,
rifampicin, roxithromycin, sulfasalazine, dihydralazine, halothane, methyldopa, minocycline, nitrofurantoin. [0074] Markers include but are not limited to genes or proteins. As described herein, the marker may be but is not limited to an inflammatory mediator, a growth factor and a reactive oxygen species. [0075] In one example, the inflammatory mediator is a cytokine. The cytokine may be but is not limited to interferon-γ (IFN-γ), interleukin (IL) IL-1β, IL-6, IL-10, IL-12, IL-17, IL-18 and tumor necrosis factor-α (TNF-α). In another example, the inflammatory mediator is a chemokine. The chemokine may be but is not limited to CCL2, CCL3, CCL4, CCL5, CCL11. [0076] In one example, the marker is a growth factor. The growth factor may be but is not limited to platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGF-β1), growth factors from the tumor-necrosis factor (TNF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP) families. [0077] In one example, the marker is a reactive oxygen species. The reactive oxygen species may be but is not limited to superoxide anion (O2-), hydrogen peroxide (H2O2), hydroxyl radical and singlet oxygen. [0078] In another aspect, provided herein is a method of treating a liver disease in a subject in need thereof, wherein an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein is to be administered to said subject, wherein the disease may be but is not limited to liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver. [0079] In another aspect, provided herein is a use of an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein in the manufacture of a medicament for the treatment of a liver disease, wherein the liver disease may be but is not limited to liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer,
primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver. [0080] In yet another aspect, provided herein is an induced pluripotent stem cell (iPSC)- derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein, for use in treating a liver disease, wherein the liver disease may be but is not limited to liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver. [0081] In yet another aspect, provided herein is an induced pluripotent stem cell (iPSC)- derived Kupffer cell (iKC) as described herein or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) as described herein, for use in therapy. [0082] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including”, “expressing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. [0083] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. [0084] Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups,
those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. EXPERIMENTAL SECTION [0085] Non-limiting examples of the invention and comparative examples will be further described in greater detail by reference to specific examples, which should not be construed as in any way limiting the scope of the invention. [0086] Materials and Methods [0087] Maintenance of iPSCs [0088] Human IMR90-iPSCs were obtained from WiCell Research Institute (Madison, WI). The cells were maintained under antibiotic-free conditions in mTESR media (StemCell Technologies, 85850) on Matrigel (Corning, 354234)-coated plates. Cells were passaged using ReLESR (StemCell Technologies, 05872) or Dispase (StemCell Technologies, 07913) as per manufacturer’s protocol whenever they reached 80% confluency. [0089] Differentiation of iPSCs to iHeps [0090] IMR90-iPSCs were differentiated into iPSC-hepatocytes (iHeps) as previously described by Cai et al., (2015). Briefly, the iPSCs were cultured to 80% confluency, then made into single cells using Cell Dissociation Buffer (Gibco, 13151014) and seeded at 1.5 x 105 cells/cm2 on the desired well plate format (i.e. 1.5 x 106 cells for a 6 well plate) and placed under hypoxic conditions (5% O2 and 5% CO2). Growth factors and media used starting from the next day to day 20 are detailed in Cai et al., (2015). Media was changed every day and hypoxic conditions were used during days 5 to 15 of differentiation. After 20 days of differentiation, iPSC-derived macrophages (iMacs) were either directly added to the iHeps or iHeps were harvested for seeding into smaller well formats for drug testing. The harvesting protocol has previously been detailed in Tasnim et al., (2016). [0091] Differentiation of iPSCs to iMacs [0092] IMR90-iPSCs were differentiated into iMacs as previously described by Takata et al., (2017). Briefly, the iPSCs were cultured to 80% confluency, then passaged using ReLESR. As ReLESR releases the cells as small cell clumps, the passage conditions were optimised to result in roughly 1 x 105 cells in each well of a 6 well plate (Day -1). Starting from the next day (Day 0) to day 16, the cells were cultured in Stempro Media, consisting of Stempro-34 SFM (GIBCO, 10639-011), supplemented with 200 ug/mL Human Transferrin
(Roche, 10-652-202-001), 1x L-Glut, 1x Pen/Strep, 0.5 mM Ascorbic Acid (Sigma, A4544) and 0.45mM MTG (Sigma, M6145). A full media change was done every other day for the next 16 days, supplemented with the following cytokines: Differentiation Day 0 (5 ng/mL BMP4, 50 ng/mL VEGF, and 2 µM CHIR99021), Differentiation Day 2 (5 ng/mL BMP4, 50 ng/mL VEGF, and 20 ng/mL FGF2), Differentiation Day 4 (15 ng/mL VEGF and 5 ng/mL FGF2), Differentiation Day 6 to 10 (10 ng/mL VEGF, 10 ng/mL FGF2, 50 ng/mL SCF, 30 ng/mL DKK-1 (RnD, 5439-DK), 10 ng/mL IL-6 (RnD, 206-IL), and 20 ng/mL IL-3), Differentiation Day 12 and 14 (10 ng/mL FGF2, 50 ng/mL SCF, 10 ng/mL IL-6, and 20 ng/mL IL-3). From day 16, the cells were cultured in 75% IMDM with GlutaMAXTM (GIBCO, 31980-030), 25% F12 (GIBCO, 11765-047), 1x N2 supplement (GIBCO, 17502- 048), 1x B27 Supplement (GIBCO, 17504-001), 0.05% BSA (GE Healthcare, SH30574) and 1x Pen/Strep, supplemented with 50ng/ml of CSF-1 (RnD, 216-MC), with a full media change every 3 days. In addition, for the first 8 days of differentiation, the cells were kept in a hypoxic incubator (5% O2 and 5% CO2), before being transferred to a standard cell culture incubator for the next 18 days. After transfer to a standard cell culture incubator, floating cells were collected every media change and resuspended back into the culture to retain the hematopoietic progenitors. After 26 days, the floating cells were collected and the purity of the iMacs was determined by flow cytometry. [0093] Differentiation of human peripheral blood monocytes (PBMCs) into monocyte- derived macrophage. [0094] Human PBMCs were purified from blood apheresis cones by ficoll gradientCytiva, 17-1440-02), before being magnetically sorted with CD14+ microbeads (Miltenyi, 130-050- 021). 1 x 106 CD14+ cells were then seeded per well of a 6 well plate in RPMI 1640 (Hyclone, SH30027.01) with 10% FBS (Biowest, S1810-500), 1x Pen/Strep, 1x Sodium Pyruvate, 1x NEAA and 1x L-Glut with 50ng/ml CSF-1 and cultured for 7 days. The purity of the monocyte-derived macrophages was then determined by flow cytometry. [0095] Co-culture of iMacs and monocyte-derived macrophages with iHeps [0096] 2 x 105 iMacs or monocyte-derived macrophages were added to 5 x 105 iHeps during a full media change (4ml) per well of a 6 well plate on Day 0. This media was comprised of Williams’ Medium E containing the following supplements: Penicillin/Streptomycin (10,000 U/mL / (10,000 μg/mL) – final conc = 1%, ITS+ - final conc= 2%, 4mM GlutaMAXTM, 30mM HEPES buffer. The concentrations of the
supplements were double that of standard conditions used due to the infrequent media change. In addition, 50ng/ml of CSF-1 was added to each well. The cells were cultured for 7 days, with a half-media change (2ml) on Day 4 consisting of the same media as described above with 100ng/ml of CSF-1, resulting in a final concentration of 50ng/ml CSF-1 in the well. The cells were collected by digesting with Accutase (StemCell, 07920) for flow cytometry, RNAseq analysis and qPCR. For pharmacological testing, the number of iHeps and iMacs were downscaled to 96-well plates while maintaining the same iHep:iMac ratio (2.5:1). [0097] Flow cytometry [0098] Standard staining procedures were used to prepare the cells for flow cytometry analysis. Briefly, cells were dissociated into single cells using the different methods described above for the various tissues, before being incubated with 100µl of antibody containing FACS buffer (1% BSA and 4mM EDTA in PBS) per 5 million cells for 20 minutes at 4°C. The cell suspension was then washed with 5ml of FACS buffer, centrifuged at 400g, and the supernatant was removed. The cells were finally resuspended in PBS containing 3uM DAPI (Invitrogen, D1306). Data was acquired by LSRII (BD Bioscience) and analyzed by Flow Jo (Tree Star, Inc.). For cell sorting, cells were sorted using FACS Aria II (BD Bioscience) or FACS Aria III (BD Bioscience). The following antibodies were used: FITC-conjugated anti- human CD14 (Biolegend, 325604), APC/Cy7-conjugated anti-human CD45 (Biolegend, 368516), PE-conjugated anti-human CD163 (R&D Systems, FAB1607P-100), Alexa Fluor 647-conjugated anti-human CX3CR1 (Biolegend, 341608, PE/Cy7-conjugated anti-human CD11b (eBioscience, 25-0118-42). [0099] Bulk RNAseq [00100] Total RNA was extracted using Arcturus PicoPure RNA Isolation kit (Thermofisher, KIT0204) according to manufacturer’s protocol. All RNAs were analyzed on Labchip GX system (Perkin Elmer, United States) for quality assessment with median RNA Quality Score of 9.15. cDNA libraries were prepared using 2ng of total RNA and 1µl of a 1:50,000 dilution of Ambion ERCC RNA Spike-in Controls (Thermofisher, 4456740) with the following modifications: 1. Use of 20mM TSO, 2. Use of 250pg of cDNA with 1/5 reaction of Nextera XT kit (Illumina, FC-131). The length distribution of the cDNA libraries was monitored using DNA High Sensitivity Reagent Kit (Perkin Elmer, CLS60672) on the
Labchip GX system (Perkin Elmer). All samples were subjected to an indexed PE sequencing run of 2x51 cycles on HiSeq 2000 (Illumina) at 16 samples per lane. [00101] Bulk RNAseq analysis [00102] Paired-end raw reads were mapped to GRCh38 human genome build. Genes were counted for reads that were mapped to genes based on GENCODEv29 gene annotation. Log2 transformed counts per million mapped read (log2CPM) and log2 transformed reads per kilobase per million mapped reads (log2RPKM) were computed. Across all samples, genes with log2CPM inter-quartile range (IQR) less than 0.5 were filtered out from subsequent differential expression gene (DEG) analysis. DEG analyses for culture condition comparisons were all done using edgeR. Selection of DEGs was done with Benjamini-Hochberg which adjusted P-values <0.05. R function ‘prcomp’ was used to perform Principal Component Analysis (PCA) on log2RPKM values. [00103] Quantitative real time PCR (qPCR) [00104] Total RNA extracted using RNeasy Plus Micro-kit (Qiagen, 74034) was quantified using a NanoDropTM ND-1000 Spectrophotometer and converted to cDNA using iScript cDNA synthesis kit (Bio-Rad Laboratories, 1708890). qPCR was performed in 7000 Fast Real-Time PCR System (Applied Biosystems, Foster City, USA) with FastStart Universal SYBR Green Master (Rox) (Roche, 04913 850 001) and primers from GeneCopoeia, Inc. (Rockville, MD, USA). Gyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as internal control. Accession numbers of tested genes are listed in Table 1. [00105] Table 1. Accession numbers of tested genes. Target Gene Gene Name Accession GAPDH glyceraldehyde-3-phosphate dehydrogenase NM_001256799.2 AFP Alpha fetoprotein NM_000295 AAT Alpha-1 antitrypsin NM_001134 ASGPR Asialoglycoprotein Receptor NM_001671 ALB albumin NM_000477.3 CYP1A2 Cytochrome P4501A2 NM_000761.5 CYP3A4 Cytochrome P4503A4 NM_017460.5 CYP2B6 Cytochrome P4502B6 NM_000767.4 CYP2C9 Cytochrome P4502C9 NM_000771.3 UGT1A3 UDP-glucuroosyltransferase 1A3 NM_019093.2 GST1A2 Glutathione S-Transferase NM_000846.3 MRP2 Multidrug resistance-associated protein 2 NM_000392 CD14 Cluster of differentiation 14 NM_001174105.1
CD32 Cluster of differentiation 32 NM_001136219.1 CD68 Cluster of differentiation 68 NM_001251.2 CD163 Cluster of differentiation 163 NM_203416.3 ID1 Inhibitor of DNA-binding protein 1 NM_002165.3 ID3 Inhibitor of DNA-binding protein 3 NM_002167.4 [00106] Enzyme-linked immunosorbent assay (ELISA) for measurement of cytokines [00107] Interleukin-6 (IL-6) levels in the media were measured using the human IL-6 ELISA kit (Abcam, ab178013) according to manufacturer’s instructions. The cytokine production from dosed cells was normalized with the viability of cells measured from the same well. This ensures that changes in cytokines are not due to changes in cell numbers that might arise upon drug treatment. The normalized cytokine level was expressed as percentage of DMSO+LPS which allowed better comparison between different batches of experiments. [00108] Cell viability assay [00109] Cell viability was examined with AlamarBlueTM cell viability assay (Thermo Fisher Scientific Inc., Dal1025) according to manufacturer’s instructions. Briefly, AlamarBlue was diluted 10-fold using PBS containing 2 mg/mL of glucose and this working solution was added to the cells and incubated for 1 hour. Fluorescence (Ex: 530nm, Em: 590nm) readings were obtained using Tecan Microplate Reader M1000 PRO. [00110] Drug administration [00111] Following set up of co-culture, the model was subjected to treatments including 100 ng/ml LPS (Sigma Aldrich, L2654), and drugs (Sigma Aldrich) (with/without LPS) for 48hr. Stock solutions of drugs were prepared in dimethyl sulfoxide (DMSO) and diluted in medium prior to use. Medium containing 0.1% DMSO was used as vehicle control except. After 48 hr, supernatant was collected cytokine measurement and cell viability in the same wells were measured. [00112] Statistical analysis [00113] Mean and standard deviation were obtained from at least three independent batches of cells. Unpaired, paired student’s y-test and one-way or two-way analysis of variance (ANOVA) were performed accordingly at an overall confidence level of 95% using Prism software (GraphPad, San Diego, CA, USA) and indicated below each figure. [00114] Results [00115] Example 1
[00116] Optimization of culture conditions allow survival and function of iHeps and iMacs [00117] In order to investigate the effects of co-culturing iHeps with iMacs, a co-culture utilising IMR90 iPSC-derived iHeps and iMacs was established and optimized (Figure 1). To ensure survival and functionality of both cell types in the desired culture period (at least one week), certain key factors had to be accounted for: Hepatocytes are high in metabolically activity and often require frequent media change for replenishment of nutrients and removal of waste. On the other hand, it would be ideal to allow the iHeps and iMacs to interact through direct cross-talk as well as through secreted soluble factors without removing these factors from the system via media exchange. To assess the performance of hepatocytes with more infrequent media changes, expression of key hepatic markers was assessed when media was changed every other day, every two days or every three days and compared to a daily media change (Figure 2). To compensate for the lower frequency of media change, the effects of 2X supplements; standard media volume (Figure 2A) and 2X supplements with 2X standard culture volume (Figure 2B) were tested. Gene expression was compared as fold change to standard hepatocyte culture conditions (daily media change with 1X supplement and standard media volume). Increasing supplements alone could maintain the expression of ALB (albumin), AAT (alpha-1-antitrypsin), cytochrome P450 (CYP)- 1A2, 3A4, 2B6 and UDP-glucuronosyltransferase (UGT)1A3, but not CYP2C19 (36 - 68% decrease), glutathione S-transferase (GST)A2 (35-66% decrease) and multidrug resistance protein-2 (MRP2; 7 to 18% decrease) (Figure 2A). In contrast, combining the increase in supplements with increase in culture volume resulted in maintenance of all hepatic markers (Figure 2B). Albumin and urea production were also maintained to 1-1.4 pg/cell/48 hrs and 126-146 pg/cell/48 hrs (Figure 2C) which is in the range of albumin and urea production. Once iHep marker and functionality were confirmed, the cells in the co-culture system were sorted via flow cytometry on Day 3 and Day 7. Flow cytometric analysis showed the presence of CD45+CD11b+CD14+ iMacs and CD45-CD11b- iHeps at Day 3 and Day 7 of co-culture (Figure 2D). [00118] Example 2 [00119] Co-culture with iHeps imparts KC-like identity to iMacs [00120] Next, the attention was turned towards the iMacs within the co-culture system. PCA analysis showed that the co-iMacs clustered much tighter together, while iMacs that
were cultured alone or in hepatocyte conditioned media (cond-iMac) were much more scattered (Figure 3A). This suggests that co-culturing iMacs in direct contact with iHeps helps maintain the identity of the iMacs better, mirroring how ex-vivo resident tissue macrophages (RTMs) rapidly lose their identity when removed from their tissue environment. DEG analysis of all the iMac groups showed that both the Day 7 iMacs and the Day 7 cond- iMacs shared an activated and inflammatory profile, upregulating genes such as TNFSF18 and ACP5 (Figure 3B). Day7 iMacs had a more migratory profile, uniquely expressing Chemokine Receptor 7 (CCR7) and Chemokine Ligand 5 (CCL5), while Day 7 cond-iMacs uniquely expressed Dishevelled Associated Activator of Morphogenesis 2 (DAAM2), a developmental regulator of the WNT pathway. The co-iMacs were much more similar to each other (Figure 2), and expressed genes relating to liver homeostasis and function such as TTR and Albumin (ALB). [00121] As there was interest in how the tissue environment might educate and impart Kupffer cell-like identity to the iMacs, the DEGs between Day 0 iMac and Day 7 co-iMacs were looked at. Day 0 iMacs expressed the granulocytic and mast cell markers Proteoglycan 2 Pro Eosinophil Major Basic Protein 2/3 (PRG2/PRG3) and Carboxypeptidase A3 (CPA3), indicating that they might be immature cells that have been newly derived from hematopoietic myeloid progenitors (Figure 3C). In contrast, Day 7 co-iMacs upregulated the angiogenic Angiopoietin-like 4 (ANGPTL4), matching the angiogenic signature observed in the Day 7 co-iHeps. Ingenuity pathway analysis revealed that the top pathway in Day 7 co- iMacs is the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway (Table 2), a key regulator of Kupffer cell identity, while the top pathway in Day 0 iMacs is the axonal guidance pathway, consisting of chemokines like C-X-C Motif Chemokine Ligand 12 (CXCL12) and C-X-C Motif Chemokine Receptor 4 (CXCR4), metalloproteases like ADAM Metallopeptidase With Thrombospondin Type 1 Motif 15 (ADAMTS15), and semaphorins like Semaphorin 3C (SEMA3C) (Table 3). This suggests that co-culturing the iMacs with iHeps activated a KC-specific programme, while the Day 0 iMacs had a more general and unspecified identity. In addition, Day 7 co-iMacs also upregulated pathways associated with tissue repair and remodelling, as well as tissue growth factors, while migratory and immune signalling related pathways were upregulated in the Day 0 iMacs (Figure 3D). These data suggest that co-culturing iMacs with iHeps is sufficient to impart a more tissue supportive and Kupffer cell-like identity to the iMacs.
[00122] Table 2. Ingenuity Pathway Analysis for genes upregulated in Day 7 co-iMacs vs Day 0 iMacs.
[00123] Table 3. Ingenuity Pathway Analysis for genes upregulated in Day 0 iMacs vs Day 7 co-iMacs.
[00124] The use of conditioned media as a surrogate of the in vivo tissue microenvironment is a popular approach, iMacs cultured in direct co-culture with iHeps may be different from iMacs cultured in PHCM. Comparing the DEGs between Day 7 cond-iMacs and Day 7 co- iMacs, the Day 7 cond-iMacs upregulated immune-related genes such as Toll-Like Receptor 4 (TLR4) and CPA3 while the Day 7 co-iMacs more highly expressed tissue residency-related Fc Gamma Receptor IIIa (FCGR3A) (Figure 3E). Pathway analysis showed that the top upregulated pathway in the Day 7 cond-iMacs was autophagy, which might indicate that conditioned media alone was insufficient to maintain proper macrophage biology in the absence of contact with other cells, although some hepatic related pathways were also upregulated as well (Figure 3F, Table 4). On the other hand, the most highly upregulated pathway in the Day 7 co-iMacs was the FXR/RXR pathway, which along with the upregulation of other anabolic pathways related to hepatic health (Table 5), suggest that co- culturing rather than conditioned media is better at inducing Kupffer cell-like identity in macrophages. [00125] Table 4. Ingenuity Pathway Analysis for genes upregulated in Day 7 cond-iMacs vs Day 7 co-iMacs.
[00126] Table 5. Ingenuity Pathway Analysis for genes upregulated in Day 7 co-iMacs vs Day 7 cond-iMacs.
[00127] Lastly, the expression of selected key Kupffer cell genes was looked at. Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA-binding protein inhibitor ID-1 (ID1) and DNA-binding protein inhibitor ID-3 (ID3), which are important markers of KC identity, were all upregulated in the co-iMacs but not in the cond-iMacs (Figure 3G). Retinoid X Receptor Alpha (RXRA), the obligate binding partner of LXR, was also upregulated in only the co-iMacs. Interestingly, the co-iMacs were also found to upregulate the expression of Heparin Binding EGF Like Growth Factor (HBEGF) and Oncostatin M (OSM), which are potent effectors of liver regeneration and development.
[00128] Altogether, the data strongly supports the hypothesis that co-culturing iMacs with iHeps induces KC-like identity in the iMacs, which in turn supports the maturation and development of the iHeps. [00129] Example 3 [00130] Gene expression confirms KC-like identity of iMacs and maturation of iHeps in co-culture [00131] The observations from the RNA sequencing analysis were confirmed by analysing gene expression of macrophage and KC-specific markers in Day 3 co-iMacs and Day 7 co- iMacs. Macrophage markers CD68, CD163, CD11b, CD32 and CD14 were all upregulated at Day 3 and Day 7 by 1.8 to 7.6 fold (Figure 4A; top panel) compared to iMac mono-culture control. Importantly, KC-specific markers ID1 and ID3 were upregulated by 3.8 fold and 3.9 fold respectively at Day 3 and by 6.3 fold and 6.5 fold respectively at Day 7 (Figure 4A; bottom panel). This suggests that macrophage phenotype is maintained during the 7 days of co-culture but KC-specific development increases in a time-dependent manner. When Day 7 co-iMacs were compared to iMacs cultured in PHCM (Day 7 cond-iMacs; without the presence of iHeps), macrophage marker upregulation compared to iMac mono-culture control were similar in both conditions (Figure 4B; top panel) but KC-specific ID1 and ID3 were upregulated to a lower extent in Day 7 cond-iMacs (2.6 fold and 2.5 fold respectively) compared to Day 7 co-iMacs (6.3 fold and 6.5 fold respectively; Figure 4B; bottom panel). [00132] Next, the RNA sequence analysis of iHep was confirmed via gene expression. With the exception of Glutathione-S transferase1A2 (GST1A2) and Multidrug Resistance Associated Protein 2 (MRP2), co-culture with iMacs improved expression of several hepatic marker genes including ALB, ^-1 antitrypsin (AAT), cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C9, CYP2B6) and UDP-glucuronosyltransferases (UGT1A3) by 1.8-53.1 fold at Day 3 and Day 7 of co-culture (Figure 4C). Importantly, AFP, a marker that is expressed at high levels in fetal hepatocytes and increases with hepatocyte maturation, had 37% lower expression at Day 3 and 37% lower expression in Day 7 iHeps as compared to Day 0 iHeps (Figure 4C). This is consistent with RNA sequencing data that showed a downregulation of AFP. [00133] Overall, the gene expression data confirms the RNA sequencing analysis findings that culturing iMacs with iHeps imparts KC-like phenotype in iMacs and supports maturation and function of the iHeps.
[00134] Example 4 [00135] Co-culture model accurately mimics clinical/in-vivo immune responses of drugs [00136] To test the application of the co-culture in detecting immune-mediated response to hepatotoxic drugs, a group of 7 drugs was carefully selected based on the following criteria: 1) confirmed reports of immune/inflammation-associated effects according to 3 databases; 2) available clinical data, or in vivo responses if the former is unavailable; and 3) known Cmax (maximum serum concentration of drug) to guide the concentration of drug used in in the in vitro model (Drug concentrations used in the system was no more than 20-fold of its Cmax. Details of selected drugs are summarized in Table 6. The drugs included: diclofenac (DIC), sulindac (SLD) leflunomide (LFM); amodiaquine (AQ), lamotrigine (LTG), penicillin (PEN), pyrazinamide (PZA). DIC, SLD and LFM have been reported to cause a decrease in interleukin-6 (IL-6); whereas AQ and LTG have been reported to cause an increase in IL-6 in patients with drug-induced liver injury. PEN and PZA were selected as negative controls as no immune-mediated effects of these drugs have been reported. The co-culture model could correctly recapitulate IL-6 decrease in DIC, SLD and LFM, IL-6 increase in AQ and LTG and no change in IL-6 in PEN and PZA-treated samples (Figure 5). Interestingly, LFM did not show a dose-dependent IL-6 decrease when iKCs were generated from iMacs using conditioned media and co-cultured with iHeps (data not shown). When iMac-derived iKC- like cells were replaced with blood Monocytes/Macrophages, none of these cytokine changes were recapitulated with the exception of SLD treatment (Figure 6). This shows, from a functional/application perspective, how iMac-iKCs are indispensable for in liver vitro models that can detect immune-mediated changes of hepatotoxicants. [00137] Table 6. Details of drugs used for testing.
[00138] In vivo, KCs have been known to release mediators that are early features of inflammatory responses. They are activated in response to inflammatory stimuli such as bacterial lipopolysaccharide (LPS) that can damage the liver at large doses in a KC- dependent manner. At smaller doses, LPS activates KCs (without causing liver injury) but sensitizes the liver to a variety of other xenobiotics. In the model, when the co-culture was co-treated with paradigm hepatotoxicants and LPS, drug-dose-dependent changes in cytokine production were observed, suggesting that the system can indeed mimic physiological responses. In contrast, such observations have not been reported in monocyte-derived macrophages in vivo, and hence, the work demonstrates the importance of liver-specific imprinting of macrophages in recapitulating responses in an in vitro liver model. [00139] Equivalents The foregoing examples are presented for the purpose of illustrating the invention and should not be construed as imposing any limitation on the scope of the invention. It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application. [00140] References [00141] K. Takata, T. Kozaki, C.Z.W. Lee, M.S. Thion, M. Otsuka, S. Lim, K.H. Utami, K. Fidan, D.S. Park, B. Malleret, Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function, Immunity 47(1) (2017) 183-198. E6. [00142] F. Tasnim, Y.C. Toh, Y. Qu, H. Li, D. Phan, B.C. Narmada, A. Ananthanarayanan, N. Mittal, R.Q. Meng, H. Yu, Functionally enhanced human stem cell derived hepatocytes in
galactosylated cellulosic sponges for hepatotoxicity testing, Molecular pharmaceutics 13(6) (2016) 1947-1957. [00143] J. Cai, J. Fisher, A. Urick, T. Wagner, K.T.M. Cayo, M. Nagaoka, S.A. Duncan, Protocol for directed differentiation of human pluripotent stem cells toward a hepatocyte fate, African Scientist 16(1) (2015) 13-26.
Claims
Claims 1. A method of generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising the steps of: a) providing an iPSC-derived macrophage (iMac); b) providing an iPSC-derived hepatocyte (iHep); c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate the iKC.
2. The method of claim 1, wherein the induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) demonstrates one or more biological characteristics of a Kupffer cell (KC).
3. The method of claim 2, wherein the biological characteristic of a Kupffer cell (KC) is selected from the group consisting of: a) expression of a macrophage marker; b) expression of a Kupffer cell (KC) marker; c) expression of a Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator; and d) expression of a marker for liver regeneration and/or development.
4. The method of claim 3, wherein the macrophage marker is selected from the group consisting of: CD68, CD163, CD11b, CD32, CD14 and combinations thereof.
5. The method of claim 3, wherein the Kupffer cell (KC) marker is selected from the group consisting of: Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA-binding protein inhibitor ID-1 (ID1) and DNA-binding protein inhibitor ID-3 (ID3).
6. The method of claim 3, wherein the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator is Retinoid X Receptor Alpha (RXRA).
7. The method of claim 3, wherein the marker for liver regeneration and/or development is selected from the group consisting of: Heparin Binding EGF Like Growth Factor (HBEGF) and Oncostatin M (OSM).
8. The method of any one of claims 1 to 7, wherein the number of iHeps to iMacs is of the ratio of about 2.5:1.
9. The method of any one of claims 1 to 8, wherein the iHeps and iMacs are incubated at a cell density of about 5 x 105 and 2 x 105 respectively per well of a 6-well plate.
10. The method of any one of claims 1 to 9, wherein the iHeps and iMacs are incubated with culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAXTM and about 30mM HEPES buffer.
11. The method of any one of claims 1 to 10, wherein the culture medium contains CSF- 1.
12. The method of any one of claims 1 to 11, wherein the concentration of CSF-1 is about 50 ng/mL.
13. The method of any one of claims 1 to 12, wherein the culture medium does not contain dexamethasone.
14. The method of any one of claims 1 to 13, wherein the culture medium does not contain primary hepatocyte conditioned media.
15. The method of any one of claims 1 to 14, wherein the iPSCs are human iPSCs.
16. The method of any one of claims 1 to 15, wherein the iPSCs are human IMR90- iPSCs.
17. The method of any one of claims 1 to 16, wherein the volume of culture media per well of a 6-well plate is about 4 mL.
18. The method of claim 17, wherein the iHep and iMac are cultured for 7 days.
19. The method of claim 18, wherein about 2 mL of culture media is aspirated from a well in the 6-well culture plate and replaced with about 2mL of newly prepared culture media of the same on Day 4.
20. A kit when used in the method of any one of claims 1 to 19, for generating an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) comprising: a) an iPSC-derived macrophage (iMac); b) an iPSC-derived hepatocyte (iHep); and c) a premixed cell culture media comprising about 1% Penicillin/Streptomycin, about 2% ITS, about 4mM GlutaMAXTM and about 30mM HEPES buffer with instructions for use.
21. An induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) obtained by the method of any one of claims 1 to 19.
22. The iKC of claim 21, wherein the iKC expresses higher levels of KC-specific markers compared to an iMac cultured in primary hepatocyte conditioned media.
23. The iKC of claim 21, wherein the iKC expresses one or more of the following biological properties of a Kupffer cell (KC): a) a macrophage marker; b) a Kupffer cell (KC) marker; c) a Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator; and d) a marker for liver regeneration and/or development.
24. The iKC of claim 23, wherein the macrophage marker is selected from the group consisting of: CD68, CD163, CD11b, CD32, CD14 and combinations thereof.
25. The iKC of claim 23, wherein the Kupffer cell (KC) marker is selected from the group consisting of: Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), DNA- binding protein inhibitor ID-1 (ID1) and DNA-binding protein inhibitor ID-3 (ID3).
26. The iKC of claim 23, wherein the Liver X Receptor/Farnesoid X Receptor (LXR/RXR) signalling pathway regulator is Retinoid X Receptor Alpha (RXRA).
27. The iKC of claim 23, wherein the marker for liver regeneration and/or development is selected from the group consisting of: Heparin Binding EGF Like Growth Factor (HBEGF) and Oncostatin M (OSM).
28. A combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep).
29. The combined cell population according to claim 28, wherein the iKC and iHep are derived from a single stem cell source.
30. The combined cell population according to any one of claims 28 and 29 for use as a model of a disease.
31. The combined cell population according to claim 30, wherein the disease is selected from the group consisting of: liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver.
32. A method of detecting an immune-mediated response to an agent comprising the steps of: a) providing an iPSC-derived macrophage (iMac); b) providing an iPSC-derived hepatocyte (iHep);
c) contacting and incubating the iMac from step (a) with the iHep from step (b) to generate a combined cell population comprising an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC); d) contacting and incubating the combined cell population from step (c) with the agent; e) detecting the presence or absence of a marker or measuring a level of said marker to detect the immune-mediated response to the agent.
33. The method according to claim 32, wherein the marker is selected from the group consisting of: an inflammatory mediator, a growth factor and a reactive oxygen species.
34. The method according to claim 33, wherein the inflammatory mediator is a cytokine.
35. The method according to claim 34, wherein the cytokine is selected from a group consisting of: interferon-γ (IFN-γ), interleukin (IL) IL-1β, IL-6, IL-10, IL-12, IL-17, IL-18 and tumor necrosis factor-α (TNF-α).
36. The method according to claim 32, wherein the agent is a hepatotoxic drug.
37. The method according to claim 36, wherein the hepatotoxic drug is selected from the group consisting of: diclofenac (DIC), sulindac (SLD) leflunomide (LFM); amodiaquine (AQ), lamotrigine (LTG), allopurinol, carbamazepine, celecoxib, clavulanate, deferasirox, erythromycin, flucloxacillin, nevirapine, phenytoin, posaconazole, propylthiouracil, rifampicin, roxithromycin, sulfasalazine, dihydralazine, halothane, methyldopa, minocycline, nitrofurantoin.
38. A method of treating a liver disease in a subject in need thereof comprising administering an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) according to claim 21 or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) according to claim 28 to said subject, wherein the disease is selected from the group consisting of: liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver.
39. Use of an induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) according to claim 21 or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) according to claim 28 in the
manufacture of a medicament for the treatment of a liver disease selected from the group consisting of: liver injury, drug-induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver.
40. An induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) according to claim 21 or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) according to claim 28, for use in treating a liver disease selected from the group consisting of: liver injury, drug- induced liver injury (DILI), liver disease, steatohepatitis, cholestasis, liver fibrosis, viral hepatitis, liver cancer, primary hepatocellular carcinoma, relapse hepatocellular carcinoma and colorectal metastasis in the liver.
41. An induced pluripotent stem cell (iPSC)-derived Kupffer cell (iKC) according to claim 21 or a combined cell population comprising an iPSC-derived Kupffer cell (iKC) and an iPSC-derived hepatocyte (iHep) according to claim 28, for use in therapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SG2022/050696 WO2024072316A1 (en) | 2022-09-28 | 2022-09-28 | Co-culture of human induced pluripotent stem cell (hipsc) − derived macrophages and hepatocytes for generation of hipsc-kupffer cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SG2022/050696 WO2024072316A1 (en) | 2022-09-28 | 2022-09-28 | Co-culture of human induced pluripotent stem cell (hipsc) − derived macrophages and hepatocytes for generation of hipsc-kupffer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024072316A1 true WO2024072316A1 (en) | 2024-04-04 |
Family
ID=90478903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2022/050696 WO2024072316A1 (en) | 2022-09-28 | 2022-09-28 | Co-culture of human induced pluripotent stem cell (hipsc) − derived macrophages and hepatocytes for generation of hipsc-kupffer cells |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024072316A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018128586A1 (en) * | 2017-01-05 | 2018-07-12 | Agency For Science, Technology And Research | Methods of generating hepatic macrophages and uses thereof |
WO2020106215A1 (en) * | 2018-11-21 | 2020-05-28 | Agency For Science, Technology And Research | Generation of mature kupffer cells |
-
2022
- 2022-09-28 WO PCT/SG2022/050696 patent/WO2024072316A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018128586A1 (en) * | 2017-01-05 | 2018-07-12 | Agency For Science, Technology And Research | Methods of generating hepatic macrophages and uses thereof |
WO2020106215A1 (en) * | 2018-11-21 | 2020-05-28 | Agency For Science, Technology And Research | Generation of mature kupffer cells |
Non-Patent Citations (5)
Title |
---|
GUREVICH I. ET AL.: "iPSC-derived hepatocytes generated from NASH donors provide a valuable platform for disease modeling and drug discovery", BIOLOGY OPEN, vol. 9, no. 12, 16 December 2020 (2020-12-16), pages 1 - 9, XP055861212, [retrieved on 20230324], DOI: 10.1242/BIO.055087 * |
LEE C.Z.W. ET AL.: "Studying tissue macrophages in vitro: are iPSC-derived cells the answer?", NATURE REVIEWS IMMUNOLOGY, vol. 18, no. 11, 23 August 2018 (2018-08-23), pages 716 - 725, XP036622986, [retrieved on 20230324], DOI: 10.1038/S41577-018-0054-Y * |
OUCHI RIE; TOGO SHODAI; KIMURA MASAKI; SHINOZAWA TADAHIRO; KOIDO MASARU; KOIKE HIROYUKI; THOMPSON WENDY; KARNS REBEKAH A.; MAYHEW : "Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids", CELL METABOLISM, CELL PRESS, UNITED STATES, vol. 30, no. 2, 30 May 2019 (2019-05-30), United States , pages 374, XP085793115, ISSN: 1550-4131, DOI: 10.1016/j.cmet.2019.05.007 * |
TAKATA K. ET AL.: "Induced-Pluripotent-Stem- Cell -Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function", IMMUNITY, vol. 47, no. 1, 18 July 2017 (2017-07-18), pages 183 - 198, XP085134422, [retrieved on 20230324], DOI: 10.1016/J.IMMUN1. 2017.06.01 7 * |
TASNIM F. ET AL.: "Generation of mature Kupffer cells from human induced pluripotent stem cells", BIOMATERIALS, vol. 192, 16 November 2018 (2018-11-16), pages 377 - 391, XP055806904, [retrieved on 20230324], DOI: 10.1016/J. BIOMATERIALS . 2018.11.01 6 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Immune regulation mechanism of Astragaloside IV on RAW264. 7 cells through activating the NF-κB/MAPK signaling pathway | |
Himburg et al. | Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells | |
US20200405757A1 (en) | Macrophage-based therapy | |
US20240026302A1 (en) | Generating arterial endothelial cell populations | |
Thomas et al. | 14-3-3σ (sigma) regulates proliferation and differentiation of multipotent p63-positive cells isolated from human breastmilk | |
Fathi et al. | Mesenchymal stem cells promote caspase expression in Molt-4 leukemia cells via GSK-3α/and ERK1/2 signaling pathways as a therapeutic strategy | |
Maraldi et al. | Role of hepatocyte growth factor in the immunomodulation potential of amniotic fluid stem cells | |
JP2019089846A (en) | Modulation of angiogenesis | |
US20230414676A1 (en) | Liver disease regulatory formulation and use thereof | |
Kim et al. | Sphere formation of adipose stem cell engineered by poly-2-hydroxyethyl methacrylate induces in vitro angiogenesis through fibroblast growth factor 2 | |
Borek et al. | BMP7 aberrantly induced in the psoriatic epidermis instructs inflammation-associated Langerhans cells | |
Yokoyama et al. | Regulation of CCl 4-induced liver cirrhosis by hepatically differentiated human dental pulp stem cells | |
US11834680B2 (en) | Single kidney cell-derived organoids | |
EP2992088B1 (en) | Cell therapy for myelodysplastic syndromes | |
McGonigle et al. | UV Irradiation of skin enhances glycolytic flux and reduces migration capabilities in bone marrow–differentiated dendritic cells | |
WO2024072316A1 (en) | Co-culture of human induced pluripotent stem cell (hipsc) − derived macrophages and hepatocytes for generation of hipsc-kupffer cells | |
Choi et al. | Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy | |
US20110293574A1 (en) | Hematopoietic stem cell growth factor | |
Maraldi et al. | Human biliary tree stem/progenitor cells immunomodulation: Role of hepatocyte growth factor | |
Vazirzadeh et al. | Galactosylation of rat natural scaffold for MSC differentiation into hepatocyte-like cells: A comparative analysis of 2D vs. 3D cell culture techniques | |
Mondragón-García et al. | Human cord blood hematopoietic cells acquire neural features when cultured in the presence of neurogenic cytokines | |
US20220387514A1 (en) | Methods of treating acute respiratory distress syndrome | |
Li et al. | Integration of Kupffer cells into human iPSC-derived liver organoids for modeling liver dysfunction in sepsis | |
TW201009077A (en) | Isolation and cultivation system for normal or tumorigenic stem cell | |
WO2023165503A1 (en) | Method for differentiating hematopoietic stem/progenitor cells into nk cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22961137 Country of ref document: EP Kind code of ref document: A1 |